US3635993A - 1,2,3,4-tetrahydro-5h-(1)benzopyrano-(3,4-a)pyridines - Google Patents
1,2,3,4-tetrahydro-5h-(1)benzopyrano-(3,4-a)pyridines Download PDFInfo
- Publication number
- US3635993A US3635993A US870278A US3635993DA US3635993A US 3635993 A US3635993 A US 3635993A US 870278 A US870278 A US 870278A US 3635993D A US3635993D A US 3635993DA US 3635993 A US3635993 A US 3635993A
- Authority
- US
- United States
- Prior art keywords
- benzopyrano
- hydroxy
- methyl
- tetrahydro
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Definitions
- This invention relates to novel chemical compositions of matter known in the art of chemistry as l,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c]pyridines and 5H-[ l] benzopyrano[3,4-c1piperidines having the Formulas Ia, b and Ila, b, respectively:
- lower-alkanoyl cycloalkyl-lower-alkyl, cycloalkyl-loweralkanoyl, lower-alkenyl, lower-alkynyl, halo-lower-alkenyl, phenyl-lower-alkyl, phenyl-lower-alkanoyl, phenyllower-alkenyl, or phenyl-lower-alkynyl.
- lower-alkyl means saturated, monovalent aliphatic radicals, including straight or branched-chain radicals of from one to six carbon atoms, as illustrated by, but not limited to methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, amyl, hexyl, and the like.
- lower-alkynyl means monovalent, aliphatic radicals, of from three to seven carbon atoms which contain at least one triple bond, and are either straight or branched-chain as illustrated by, but not limited to l-(2-propynyl), l-(l-methyl-Z-propynyl), l-(2- heptynyl), and the like.
- cycloalkyl means cyclic, saturated aliphatic radicals of from three to eight carbon atoms, as illustrated by, but not limited to cyclopropyl, cyclobutyl, 2-methylcyclobutyl, cyclohexyl, 4-methylcyclohexyl, cyclooctyl, and the like.
- lower-alkanoyl means saturated, monovalent, aliphatic radicals derived from a monocarboxylic acid, including straight or branched-chain radicals of from one to six carbon atoms, as illustrated by, but not limited to formyl, acetyl, propionyl, rat-methylpropionyl, butyryl, hexanoyl, and the like.
- benzene ring of phenyl can bear any number and kind of substituents such as would occur to the man skilled in organic chemistry. Solely for illustration, and without limitation, such substituents include lower-alkyl, lower-alkoxy, halo (chloro, bromo, iodo, or iiuoro), nitro, lower-alkylmercapto, and the like.
- the compounds of Formulas la, b where R, is hydrogen are prepared by reacting an 8-alkyl-l0-hydroxy-5-oxo- 1,2,3,4 tetrahydro-5H-[l]benzopyrano[3,4-c1pyridine or a 10 alkyl 8 hydroxy-S-oxo-l,2,3,4-tetrahydro-5H-[1]- benzopyrano[3,4-c]pyridine, having-the respective Formulas IIIa. and IIIb, with a lower-alkyl magnesium halide as illustrated by the equation:
- RlMgHal where R R and R have the meanings given herein above, and Hal represents halogen.
- the reaction is carried out in an organic solvent inert under the conditions of the reaction. Suitable solvents are diethyl ether, dibutyl ether, tetrahydrofuran, anisole, pyridine, and the like.
- the compounds of Formula IIIa, b in turn are prepared by reacting a l-R -3-carbo-lower-alkoxy-4-piperi done of Formula IV with a 5-alkylresorcinol of Formula V.
- the reaction is carried out in a mixture of concentrated sulfuric acid and phosphorus oxychloride or in the presence of other acidic condensation agents such as aluminum chloride, hydrogen chloride, or polyphosphoric acid and is illustrated by the equation:
- the ring closure of the 1-R -3-carbo-lower-alkoxy-4-piperidone with the S-alkylresorcinol can take place either by cycliza tion at the 2-position of the 5-alkylresorcin0l, as indicated by the arrow (a), to produce the 8-alkyl-10-hydroxy-5- oXo-1,2,3,4-tetrahydro 5H [l]benzopyrano[3,4-c]pyridines of Formula IIIa or by cyclization at the 4-position of the S-alkylresorcinol, as indicated by the arrow (b), to produce the l-alkyl-8-hydroxy-5-0xo-l,2,3,4-tetrahydro- H-[1]benzopyrano[3,4-cJpyridines of Formula IIIb.
- either the compounds of Formula 11111 or of Formula IIIb are produced by either S-methylresorcinol (R is CH or by 5-(3-methyl-2-octy1)resorcinol (R is CHCH CHCH C H but in the latter case, the predominant products are the compounds of Formula IIIa owing to the partial steric hindrance of the 4-position of the resorcinol by the rather bulky 3-methyl-2-octyl group in the adjacent 5-position which inhibits cyclization at the 4-position.
- the intermediate 1 R -3-carbo-lower-alkoxy-4-piperidones of Formula IV are prepared by the method of Prill and McElvain, J. Am. Chem. Soc. 55, 1233(1933) and of McElvain and Vozza, J. Am. Chem. Soc. 71, 896(1948).
- the compounds of Formulas Ia and Ib where R is hydrogen are also advantageously prepared by catalytically debenzylating, with hydrogen in the presence of a catalyst, the compounds of Formulas Ia, b hereinabove where R is benzyl.
- the reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example methanol, ethanol, isopropanol, and the like.
- Suitable catalysts are platinum or palladium-on-charcoal.
- a preferred catalyst is palladium-on-charcoal.
- the compounds of Formulas Ia, b or IIa, b, where R is cycloalkyl-lower-alkyl, lower-alkenyl, lower-alkynyl, halo lower alkenyl, phenyl-lower-alkyl, phenyl-loweralkenyl, or phenyl-lower-alkynyl are prepared by reacting the corresponding compounds of Formuas -Ia, b or IIa, b, where R is hydrogen with a cycloalkyl-lower-alkyl, lower-alkenyl, lower-alkynyl, halo-lower-alkenyl, phenyllower-alkyl, phenyl-lower-alkeny, or phenyl-lower-alkynyl halide, respectively.
- the reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example methanol, ethanol, isopropanol, or dimethylformamide, and in the presence of an acid-acceptor.
- the purpose of the acid-acceptor is to take up the hydrogen halide split out during the course of the reaction and is a basic substance which forms water-soluble salts readily separable from the reaction mixture.
- Suitable acidacceptors are alkali metal carbonates or bicarbonates, for example sodium or potassium carbonate, or bicarbonate, or alkali metal hydroxides, for example sodium or potassium hydroxide.
- the reaction can also be carried out in the presence of a molar excess of the bases of Formulas Ia, b or IIa, b where R is hydrogen.
- a preferred acidacceptor is sodium carbonate, and a preferred solvent is ethanol.
- the reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example benzene, toluene, xylene, and the like, and in the presence of a basic catalyst, for example pyridine, triethylamine, dimethylaniline, and the like.
- a basic catalyst for example pyridine, triethylamine, dimethylaniline, and the like.
- a preferred solvent is benzene
- a preferred basic catalyst is pyridine.
- the compounds of Formulas Ia, b or Ha, b where R is cycloalkyl lower alkyl and phenyl-lower-alkyl can also be prepared by reducing, with an alkali metal aluminum hydride, the compounds of Formulas Ia, b or IIa, b where R, is cycloalkyl-lower-alkanoyl or phenyl-loweralkanoyl, respectively, and where R, is hydrogen or loweralkyl.
- the reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example diethyl ether, tetrahydrofuran, dibutyl ether, and the like.
- the 8 alkyl 10- hydroxy-S,5-di-lower-alkyl-5H-[1]- benzopyrano[3,4-c1piperidines and l0-alkyl-8-hydroxy-5, S-di-lower-alkyl-SH- 1 ]benzopyrano [3 ,4-c] piperidines of Formulas Ila and 11b, respectively, are prepared by reducing with hydrogen over a suitable catalyst the 8-alkyl- 10 hydroxy-S,S-di-lower-alkyl-1,2,3,4-tetrahydro-5H-[1] benzopyrano[3,4-c1pyridines and l0-alkyl-8-hydroxy-5,5- di lower alkyl-1,2,3,4-tetrahydro-5H-[1]benzopyrano [3,4-c]pyridines of Formulas Ia and lb, respectively, where R R and R have the meanings given above and R is hydrogen, lower-alkyl, lower-alkan
- the reaction is carried out in an organic solvent inert under the conditions of the reaction, for example, methanol, ethanol, isopropanol, and the like.
- Suitable catalysts include palladium-on-charcoal, platinum, Raney nickel and the like.
- a preferred catalyst is Raney nickel.
- ester and ether derivatives of the compounds of Formulas Ia, b and IIa, b that is the compounds where R, is lower-alkyl, lower-alkanoyl, carbamyl, N-loweralkylcarbamyl, N,N-di-lower-alkylcarbamyl, or phosphonyl are prepared by reacting the corresponding com pounds where R, is hydrogen, preferably in the presence of a basic catalyst, with a lower-alkyl halide, to produce the compound where R, is loWer-alkyl with a lower-alkanoic anhydride (or mixed anhydride), to produce the compounds where R; is lower-alkanoyl; with a molar equivalent of phosgene followed by reaction of the resulting chloroformate with ammonia, a lower-alkylamine, or a di-lower-alkylamine, to produce the compounds where R, is, respectively, carbamyl, N-lower-alkylc
- the acid-addition salts of the bases herein described are the form in which the bases are most conveniently prepared for use and are the full equivalents of the subject matter specifically claimed.
- the acid moieties or anions in these salt forms are in themselves neither novel nor critical and therefore can be any acid anion or acid-like substance capable of salt formation with the free base form of the compounds.
- the preferred type of salts are watersoluble pharmacologically-acceptable salts, that is, salts whose anions are relatively innocuous to the animal organisms in pharmacological doses of the salts, so that the beneficial physiological properties inherent in the free base are not vitiated by side effects ascribable to the anions; in other words, the latter do not substantially affect the pharmacological properties inherent in the cations.
- hydrochloride salt In practicing the invention, it has been found convenient to form the hydrochloride salt.
- other appropriate pharmacologically-acceptable salts within the scope of the invention are those derived from mineral acids such as hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfamic acid, and sulfuric acid; and organic acids such as acetic acid, citric acid, tartaric acid, lactic acid, methanesulfonic acid, ethanesulfonic acid, quinic acid and the like, giving the hydrobromide, hydroiodide, nitrate, phosphate, sulfamate, sulfate, acetate, citrate, tartrate, lactate, methanesulfonate, ethanesulfonate, and quinate, respectively.
- mineral acids such as hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfamic acid, and sulfuric acid
- organic acids
- pharmacologically-acceptable salts are preferred, those having toxic anions are also useful. All acid-addition salts are useful intermediates as sources of the free base form even if the particular salt per se is not desired as the final product, as for example when the salt is formed only for purposes of purification or identification, or when it is used as an. intermediate in preparing a pharmacologically-acceptable salt by ion-exchange procedures.
- the compounds of Formulas Ia, b and Ha, I have been shown to possess CNS. and cardiovascular activity as evidenced by gross overt changes induced by intravenous administration in mice in standard tests involving observations of psychomotor activity, reactivity to stimuli, and ability to perform normal, non-conditioned motor tasks, This activity indicates their usefulness as psychotropic agents.
- the compounds can be prepared for use by dissolving under sterile conditions a salt form of the compounds in water (or an equivalent amount of a non-toxic acid if the free base is used), or in a physiologically compatible aqueous medium such as saline, and stored in ampoules for intramuscular injection.
- they can be incorporated in unit dosage form as tablets or capsules for oral administration either alone or in combination with suitable adjuvants such as calcium carbonate, starch, lactose, talc, magnesium stearate, gum acacia, and the like.
- the compounds can be formulated for oral administration in aqueous alcohol, glycol, or oil solutions or oil-water emulsions in the same manner as conventional medicinal substances are prepared.
- EXAMPLE 2 5 ,5 -dimethyl-1 0-hydroxy-8- 3 methyl-2-octyl- 1 ,2,3 ,4-tetrahydro-5H-[11benzopyrano [3 ,4-c] pyridine
- A 3 benzyl 10 hydroxy 8 (3 methyl 2- octyl) 5 oxo l,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine hydrochloride-1 benzyl 3- carbethoxy 4 piperidone hydrochloride, (11 g., 0.037 mole) was added in portions to 10.2 g.
- EXAMPLE 3 3 allyl-5,5-dimethyl 10 hydroxy-8-(3-methyl-2-octyl)- 1,2,3,4 tetrahydro-SH-[l ]benzopyrano-[3,4-c1pyridine hydrochloride
- EXAMPLE 4 3 (trans-3-chloroallyl)-5,5-dimethyl-l0-hydroxy-8-(3- methyl-2-octyl 1,2,3,4 tetrahydro-5H[l]benzoypyrano- [3,4-c]pyridine hydrochloride was prepared from 1.6 g. (0.004 mole) of 5,5-dimethyl-l0-hydroxy-8-(3-methyl-2- octyl)-1,2,3,4-tetrahydro-5H-[ l]benzopyrano[3,4 c]pyridine, 0.48 g. (0.004 mole) of trans-1,3-dichloro-l-propene, 0.6 g.
- EXAMPLE 5 10-hydroxy-3-(Z-propynyl)-5,5,8-trimethyl-1,2,3,4- tetrahydro-5H-[ 1]benzopyrano 3,4-c] pyridine
- A 3-benzyl-10-hydroxy-8-methyl-5-oxo-1,2,3,4-tetratetrahydro-SH-[1]benzopyrano[3,4 c] pyridine.1-benzyl-3-carbethoxy 4 piperidone hydrochloride, (104 g., 0.33 mole) was mixed with g. (0.4 mole) of S-methylresorcinol, and the mixture treated dropwise over a period of one hour with 160 ml. of concentrated sulfuric acid.
- EXAMPLE 7 5,5 dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-3-(2-propynyl) -1,2,3,4-tetrahydro-5H-[l]-benzopyrano[3,4 c] pyridine hydrochloride
- 10-hydroxy-8-(3-methyl 2 octyl)-5-oxo-1,2,3,4- tetrahydro-5H-[1]benzopyrano[3,4 c]pyridine was prepared by catalytic debenzylation of 3-benzyl-10-hydroxy- 8 (3-methy1-2-octyl)-5-oxo 1,2,3,4 tetrahydro-SH-[l] benzoypyrano[3,4-c]pyridine in 200 ml.
- EXAMPLE 8 5,5 di (1 hexyl) 10 hydroxy 3 methyl 8 -(3- methyl 2 octyl) 1,2,3,4 tetrahydro 5H [1] benzopyrano[3,4-c]pyridine
- 10 hydroxy 3 methyl 8- (3-methyl 2 octyl) 1,2,3,4 tetrahydro 5H [l] benzopyrano[3,4-c]pyridine is reacted with n-hexyl magnesium bromide in anisole to give 5,5-di-(1-hexyl)-10-hydroxy 3 methyl 8 (3 methyl 2 octyl) 1,2,3,4- tetrahydro 5H [1]benzopyrano[3,4-c]pyridine.
- EXAMPLE 25 -methoxy-8-(3-methyl-2-octy1)-3,5,5-trimethyl-1,2,3,4 tetrahydro-5H-[ 1] -b enzopyrano 3 ,4-c] pyridine
- 10-hydroxy-8-(3-methyl-2-0ctyl)-3,5,5-trimethyl 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4- c] pyridine with methyl iodide in the presence of sodium ethoxide, there is obtained 10 methoxy-8-(3-methy1-2- octyl) 3,5,5 trimethyl 1,2,3,4 tetrahydro 5H [1]- benzopyrano[3,4-c] pyridine.
- EXAMPLE 32 3 -allyl-5,5-dimethy1-10-hydroxy-8-( 3 -methyl2-octyl) 5H-[1]benzopyrano[3 ,4-c] piperidine Following a procedure similar to that described in Example 3 hereinabove, 5,5-dimethyl-10-hydroxy-8-(3-methyl 2 octyl)-5H-[1]benzopyrano[3,4-c]piperidine is reacted with 3-bromo-1-propene in absolute ethanol in the presence of anhydrous sodium carbonate to give 3-allyl- 5,5 dimethyl 10 hydroxy-S-(3-methyl-2-octyl)-5H-[1] benzopyrano[3,4-c]piperidine.
- EXAMPLE 43 8 hydroxy 1O methyl 5 oxo 1,2,3,4 tetrahydro- 5H [1]benz0pyrano[3,4-c] pyridine is prepared by catalytic debenzylation of 3 benzyl 8 hydroxy 10- methyl 5 oxo 1,2,3,4 tetrahydro 5H [1]benzopyran0[3,4-c]pyridine according to the procedure described above in Example 5-B.
- EXAMPLE 44 8 hydroxy 5,5,10 trimethyl 1,2,3,4 tetrahydro- 5H [1]benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy 10 methyl 5 oxo 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine with methyl magnesium iodide according to the procedure described above in Example 6,.
- EXAMPLE 45 8 hydroxy 3,5,5,10 tetramethyl 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c] pyridine is prepared by reaction of 8 hydroxy 10 methyl 5,5 dimethyl- 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4-c]pyridine with methyl bromide in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
- EXAMPLE 47 8 hydroxy 1O methyl 5,5 dihexyl 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy 10 methyl 5 oxo l,2,3,4- tetrahydro 5H [l]benzopyrano[3,4 c]pyridine with n-hexyl magnesium bromide according to the procedure described above in Example 6.
- EXAMPLE 49 3 acetyl 8 hydroxy 5,5,10 trirnethyl l,2,3,4- tetrahydro 5H [1]benzopyrano[3,4-c]pyridine is pre pared by reacting 8-hydroXy-5,5,IO-trimethyl-l,2,3,4-tetrahydro 5H [1]benzopyrano[3,4 c]pyridine with an equimolar amount of acetyl chloride in a benzene solution and in the presence of triethylamine according to the procedure described above in Example 10.
- EXAMPLE 50 3 phenylacetyl 8 hydroxy 5,5,10 trimethyl 1,2, 3,4 tetrahydro -5H [l]benzopyrano[3,4-c1pyridine is prepared by reacting 8 hydroxy 5,5,10 trimethyl- 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine with phenylacetyl chloride in a benzene solution and in the presence of pyridine according to the procedure described above in Example 11.
- EXAMPLE 51 3 (2 phenylethyl) 8 hydroxy 5,5,10 trimethyl- 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine is prepared by reacting 3 phenylacetyl 8 hydroxy- 5,5,10 trimethyl 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4-c] pyridine with lithium aluminum hydride in a tetrahydrofuran solution according to the procedure described above in Example. 12.
- pyridine is prepared by reacting 8-hydroxy-5,5,10-trimethyl-1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c]pyridine with 1-(2,4,6-tribromophenyl)ethyl bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
- EXAMPLE 55 3-[4-(4 nitropheny1)butyl] 8 hydroxy-5,5,10-trimethyl-l,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c] pyridine is prepared by reacting 8 hydroxy-5,5,10-trimethyl-1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c] pyridine with 4-(4-nitrophenyl)butyl bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
- EPQAMPLE 5 6 3- ⁇ 3-[1-(3,4-methylenedioxyphenyl) 1 butenyl] ⁇ -8- hydroxy-5,5,IO-trimethyl 1,2,3,4 tetrahydro 5H [1] benzopyrano[3,4-c1pyridine is prepared by reacting 8-hydroxy-5,5,l0-trimethyl-1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c]-pyridine with 3 [3,4 methylenedioxyphenyl)-1-butenyl1bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
- EXAMPLE 5 8 3 ⁇ 3-[1-(4-acetylaminophenyl)-l-butenyl] ⁇ 8 hydroxy-5,5,10-trimethyl 1,2,3,4 tetrahydro-5H-[11benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy-5,5,10-trirnethyl 1,2,3,4 tetrahydro-5H-[11benzopyrano[3,4-c]pyridine with 3 [1 (4-acetylaminophenyl) 1 butenylJbromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
- EXAMPLE 60 3-cyclopropylcarbonyl 8 hydroxy-5,5,IO-tri-methyl- 1,2,3,4 tetrahydro 5H-[1]benzopyrano[3,4-c]pyridine is prepared by reacting 8-hydroxy-5,5,10-trimethyl-1,2,3,4- tetrahydro 5H [1]benzopyrano[3,4-c] pyridine With cyclopropylcarbonyl chloride in a benzene solution and in the presence of pyridine according to the procedure described above in Example 21.
- EXAMPLE 65 3-(trans 3 chloroallyl)-8-hydroxy-5,5,IO-trimethyl- 1,2,3,4-tetrahydro 5H [l]benzopyrano[3,4-c] pyridine is prepared by reacting 8-hydroxy-5,5,lO-trimethyl-1,2,3,4- tetrahydro-5H-[l]benzopyrano[3,4-c] pyridine with trans- 1,3-dichloro-1-propene in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 4.
- EXAMPLE 66 S-acetoxy 3,5,5,10 tetramethyl-1,2,3,4-tetrahydro- 5l-I-[l]benzopyrano[3,4-c]pyridine is prepared by reacting 8-hydroxy-3,5,5,IO-tetramethyl 1,2,3,4 tetrahydro- 5H-[l]bcnzopyrano[3,4-c] pyridine with acetic anhydride according to the procedure described above in Example 24.
- EXAMPLE 67 8 methoxy-3,5,5,IO-tetramethyl 1,2,3,4 tetrahydro- 5H-[l]benzopyrano[3,4-c] pyridine is prepared by reacting 8-hydroxy-3,5,5,IO-tetramethyl 1,2,3,4 tetrahydro- 5H-[l]benzopyrano[3,4-c]pyridine with methyl iodide in the presence of sodium ethoxide according to the procedure described above in Example 25.
- EXAMPLE 69 8-(N-methylcarbamyloxy) 3,5,5,l0 tetra1nethyl-l,2, 3,4-tetrahydro 5H [l]benzopyrano[3,4-c]pyridine is prepared by reacting 8-hydroxy-3,5,5,l0-tetramethyl-1,2, 3,4-tetrahydro 5H [l]benzopyrano[3,4-c]pyridine with an equimolar amount of phosgene in the presence of dimethylaniline, and reacting the resulting chloroformate with methylamine according to the procedure described above in Example 27.
- EXAMPLE 7O 8 (N,N dimethylcarbamyloxy) 3,5,5,l0 tetramethyl 1,2,3,4 tetrahydro 5H [l]benzopyrano[3, 4-c]pyridine is prepared by reacting 8-hydroxy-3,5,5,10- tetramethyl 1,2,3,4 tetrahydro 5H[l]benzopyrano [3,4-c1pyridine with an equimolar amount of phosgene in the presence of dimethylaniline, and reacting the resulting chloroformate with dimethylamine according to the procedure described above in Example 28.
- R is lower-alkyl; R is methyl or 3-methy1-2- octyl; R is hydrogen, lower-alkyl, cycloalkyl-lower-alkyl, containing from three to eight ring carbon atoms in the cycloalkyl moiety, lower-alkenyl, lower-alkynyl, halo-lower-alkenyl and R is hydrogen.
- R is phenyl-lower-alkyl, and R is hydrogen.
- R is 3- methyl-Z-octyl; R is lower-alkyl; and R is hydrogen.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
A NEW SERIES OF 1,2,3,4-TETRAHYDRO-5H-(1)BENZOPYRANO(3,4-C) PYRIDINES AND 5H-(1) BENZOPYRANO(3,4-C)PIPERINDINES, HAVING C.N.S. AND CARDIOVASCULAR ACTIVITY.
Description
United States Patent 0 3,635,993 1,2,3,4-TETRAHY DRO-5I-I-[11BENZOPYRANO- [3,4-a1PYRIDINES Harry G. Pars, Lexington, Felix E. Granchelli, Arlington, and Raj K. Razdan, Belmont, Mass., assignors to Arthur D. Little, Inc., Cambridge, Mass.
No Drawing. Original application May 29, 1967, Ser. No. 642,223, now Patent No. 3,514,464, dated May 26, 1970. Divided and this application Oct. 30, 1969, Ser.
Int. Cl. C07d 31/28 U.S. Cl. 260-297 H 14 Claims ABSTRACT OF THE DISCLOSURE A new series of 1,2,3,4-tetrahydro-5H-[1]benzopyrano- [3,4-c]pyridines and SH-[l]benzopyrano[3,4-c]piperidines, having CNS. and cardiovascular activity.
This application is a division of our prior copending application, Ser. No. 642,223, filed May 29, 1967, which has matured into Pat. No. 3,514,464 granted on May 26, 1970.
This invention relates to novel chemical compositions of matter known in the art of chemistry as l,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c]pyridines and 5H-[ l] benzopyrano[3,4-c1piperidines having the Formulas Ia, b and Ila, b, respectively:
and to 5-oxo-1,2,3,4-tetrahydro-5H- 1 ]benzopyrano[ 3,4- c]pyridines, useful as intermediates for the preparation of the compounds of Formulas la, b and Ila, b, and having the Formulas Illa, b:
lower-alkanoyl, cycloalkyl-lower-alkyl, cycloalkyl-loweralkanoyl, lower-alkenyl, lower-alkynyl, halo-lower-alkenyl, phenyl-lower-alkyl, phenyl-lower-alkanoyl, phenyllower-alkenyl, or phenyl-lower-alkynyl.
As used herein, the term lower-alkyl means saturated, monovalent aliphatic radicals, including straight or branched-chain radicals of from one to six carbon atoms, as illustrated by, but not limited to methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, amyl, hexyl, and the like.
As used herein, the term lower-alkenyl means monovalent, aliphatic radicals of from three to seven carbon atoms which contain at least one double bond, and are either straight or branched-chain, as illustrated, but not limited to 1 (2 propenyl), 1 (3 methyl-Z-propenyl), 1-(1,3-dimethyl-2-propenyl), 1-(2-hexenyl), and the like.
As used herein, the term lower-alkynyl means monovalent, aliphatic radicals, of from three to seven carbon atoms which contain at least one triple bond, and are either straight or branched-chain as ilustrated by, but not limited to l-(2-propynyl), l-(l-methyl-Z-propynyl), l-(2- heptynyl), and the like.
As used herein, the term cycloalkyl means cyclic, saturated aliphatic radicals of from three to eight carbon atoms, as illustrated by, but not limited to cyclopropyl, cyclobutyl, 2-methylcyclobutyl, cyclohexyl, 4-methylcyclohexyl, cyclooctyl, and the like.
As used herein, the term lower-alkanoyl means saturated, monovalent, aliphatic radicals derived from a monocarboxylic acid, including straight or branched-chain radicals of from one to six carbon atoms, as illustrated by, but not limited to formyl, acetyl, propionyl, rat-methylpropionyl, butyryl, hexanoyl, and the like.
As used herein, the terms phenyl-lower-alkyl, phenyllower-alkanoyl, "phenyl-lower-alkenyl, and phenyllower-alkynyl mean a monovalent radical consisting of a phenyl nucleus bonded to the rest of the molecule through, respectively, a divalent lower-alkylene radical of from one to four carbon atoms as illustrated by, but not limited to methylene, 1,1-ethylene, 1,2-ethylene, 1,3- propylene, 1,2-propylene, 1,4-butylene, and the like, or through a divalent lower-alkenylene radical of from two to four carbon atoms, as illustrated by, but not limited to 1,2-ethenylene, 1,3-(1-propenylene), 1,3-(1-butenylene), 1,4-(2-butenylene), and the like, or through a divalent lower-alkynylene radical of from two to four carbon atoms, as illustrated by, but not limited to 1,2-ethynylene, 1,3-propynylene, 1,3-(1-butynylene), and the like. Here and elsewhere throughout this specification, it will be understood the benzene ring of phenyl can bear any number and kind of substituents such as would occur to the man skilled in organic chemistry. Solely for illustration, and without limitation, such substituents include lower-alkyl, lower-alkoxy, halo (chloro, bromo, iodo, or iiuoro), nitro, lower-alkylmercapto, and the like.
The compounds of Formulas la, b where R, is hydrogen are prepared by reacting an 8-alkyl-l0-hydroxy-5-oxo- 1,2,3,4 tetrahydro-5H-[l]benzopyrano[3,4-c1pyridine or a 10 alkyl 8 hydroxy-S-oxo-l,2,3,4-tetrahydro-5H-[1]- benzopyrano[3,4-c]pyridine, having-the respective Formulas IIIa. and IIIb, with a lower-alkyl magnesium halide as illustrated by the equation:
Illa,
RlMgHal where R R and R have the meanings given herein above, and Hal represents halogen. The reaction is carried out in an organic solvent inert under the conditions of the reaction. Suitable solvents are diethyl ether, dibutyl ether, tetrahydrofuran, anisole, pyridine, and the like. It is preferred to add a solution of the 8-alkyl-l0-hydroxy-5-oxol,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c]pyridine or 10-alkyl 8 hydroxy-S-oxo-1,2,3,4-tetrahydro-SH-[1] benzopyrano[3,4-c] pyridine in a pyridine or anisole solution, or in a mixture of these solvents, to a solution of the Grignard reagent in anisole.
The compounds of Formula IIIa, b in turn are prepared by reacting a l-R -3-carbo-lower-alkoxy-4-piperi done of Formula IV with a 5-alkylresorcinol of Formula V. The reaction is carried out in a mixture of concentrated sulfuric acid and phosphorus oxychloride or in the presence of other acidic condensation agents such as aluminum chloride, hydrogen chloride, or polyphosphoric acid and is illustrated by the equation:
IIIb
where R and R are defined as above, and Alk is loweralkyl.
As indicated by the reaction scheme above, the ring closure of the 1-R -3-carbo-lower-alkoxy-4-piperidone with the S-alkylresorcinol can take place either by cycliza tion at the 2-position of the 5-alkylresorcin0l, as indicated by the arrow (a), to produce the 8-alkyl-10-hydroxy-5- oXo-1,2,3,4-tetrahydro 5H [l]benzopyrano[3,4-c]pyridines of Formula IIIa or by cyclization at the 4-position of the S-alkylresorcinol, as indicated by the arrow (b), to produce the l-alkyl-8-hydroxy-5-0xo-l,2,3,4-tetrahydro- H-[1]benzopyrano[3,4-cJpyridines of Formula IIIb. Generally either the compounds of Formula 11111 or of Formula IIIb are produced by either S-methylresorcinol (R is CH or by 5-(3-methyl-2-octy1)resorcinol (R is CHCH CHCH C H but in the latter case, the predominant products are the compounds of Formula IIIa owing to the partial steric hindrance of the 4-position of the resorcinol by the rather bulky 3-methyl-2-octyl group in the adjacent 5-position which inhibits cyclization at the 4-position.
The intermediate 5-methyland 5-(3-methyl-2-octyl)- resorcinols of Formula V are know in the art.
The intermediate 1 R -3-carbo-lower-alkoxy-4-piperidones of Formula IV are prepared by the method of Prill and McElvain, J. Am. Chem. Soc. 55, 1233(1933) and of McElvain and Vozza, J. Am. Chem. Soc. 71, 896(1948).
The compounds of Formulas Ia and Ib where R is hydrogen are also advantageously prepared by catalytically debenzylating, with hydrogen in the presence of a catalyst, the compounds of Formulas Ia, b hereinabove where R is benzyl. The reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example methanol, ethanol, isopropanol, and the like. Suitable catalysts are platinum or palladium-on-charcoal. A preferred catalyst is palladium-on-charcoal.
The compounds of Formulas Ia, b or IIa, b, where R is cycloalkyl-lower-alkyl, lower-alkenyl, lower-alkynyl, halo lower alkenyl, phenyl-lower-alkyl, phenyl-loweralkenyl, or phenyl-lower-alkynyl are prepared by reacting the corresponding compounds of Formuas -Ia, b or IIa, b, where R is hydrogen with a cycloalkyl-lower-alkyl, lower-alkenyl, lower-alkynyl, halo-lower-alkenyl, phenyllower-alkyl, phenyl-lower-alkeny, or phenyl-lower-alkynyl halide, respectively. The reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example methanol, ethanol, isopropanol, or dimethylformamide, and in the presence of an acid-acceptor. The purpose of the acid-acceptor is to take up the hydrogen halide split out during the course of the reaction and is a basic substance which forms water-soluble salts readily separable from the reaction mixture. Suitable acidacceptors are alkali metal carbonates or bicarbonates, for example sodium or potassium carbonate, or bicarbonate, or alkali metal hydroxides, for example sodium or potassium hydroxide. The reaction can also be carried out in the presence of a molar excess of the bases of Formulas Ia, b or IIa, b where R is hydrogen. A preferred acidacceptor is sodium carbonate, and a preferred solvent is ethanol.
The compounds of Formulas Ia, b or IIa, b where R is lower-alkanoyl, cycloalkyl-lower-alkanoyl, or phenyllower-alkanoyl are prepared by reacting the corresponding compounds of Formulas Ia, b or IIa, b where R is hydrogen with an acid halide or anhydride of a loweralkanoic, cycloalkyl lower alkanoic, or phenyl-loweralkanoic acid, respectively. The reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example benzene, toluene, xylene, and the like, and in the presence of a basic catalyst, for example pyridine, triethylamine, dimethylaniline, and the like. A preferred solvent is benzene, and a preferred basic catalyst is pyridine.
The compounds of Formulas Ia, b or Ha, b where R is cycloalkyl lower alkyl and phenyl-lower-alkyl can also be prepared by reducing, with an alkali metal aluminum hydride, the compounds of Formulas Ia, b or IIa, b where R, is cycloalkyl-lower-alkanoyl or phenyl-loweralkanoyl, respectively, and where R, is hydrogen or loweralkyl. The reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example diethyl ether, tetrahydrofuran, dibutyl ether, and the like.
The 8 alkyl 10- hydroxy-S,5-di-lower-alkyl-5H-[1]- benzopyrano[3,4-c1piperidines and l0-alkyl-8-hydroxy-5, S-di-lower-alkyl-SH- 1 ]benzopyrano [3 ,4-c] piperidines of Formulas Ila and 11b, respectively, are prepared by reducing with hydrogen over a suitable catalyst the 8-alkyl- 10 hydroxy-S,S-di-lower-alkyl-1,2,3,4-tetrahydro-5H-[1] benzopyrano[3,4-c1pyridines and l0-alkyl-8-hydroxy-5,5- di lower alkyl-1,2,3,4-tetrahydro-5H-[1]benzopyrano [3,4-c]pyridines of Formulas Ia and lb, respectively, where R R and R have the meanings given above and R is hydrogen, lower-alkyl, lower-alkanoyl, cycloalkyllower-alkyl, cycloalkyl-lower-alkanoyl, phenyl lower-alkanoyl, or phenyl-lower-alkyl. The reaction is carried out in an organic solvent inert under the conditions of the reaction, for example, methanol, ethanol, isopropanol, and the like. Suitable catalysts include palladium-on-charcoal, platinum, Raney nickel and the like. A preferred catalyst is Raney nickel.
The ester and ether derivatives of the compounds of Formulas Ia, b and IIa, b, that is the compounds where R, is lower-alkyl, lower-alkanoyl, carbamyl, N-loweralkylcarbamyl, N,N-di-lower-alkylcarbamyl, or phosphonyl are prepared by reacting the corresponding com pounds where R, is hydrogen, preferably in the presence of a basic catalyst, with a lower-alkyl halide, to produce the compound where R, is loWer-alkyl with a lower-alkanoic anhydride (or mixed anhydride), to produce the compounds where R; is lower-alkanoyl; with a molar equivalent of phosgene followed by reaction of the resulting chloroformate with ammonia, a lower-alkylamine, or a di-lower-alkylamine, to produce the compounds where R, is, respectively, carbamyl, N-lower-alkylcarbamyl, or N,N-di-lower-alkylcarbamyl; or with one molar equivalent amount of phosphorus oxychloride followed by reaction of the resulting dichlorophosphinate with aqueous sodium or potassium carbonate, to produce the compounds where R, is phosphonyl. Suitable solvents are benzene, toluene, xylene, and the like, and suitable basic catalysts are alkali metal carbonates, bicarbonates, or hydroxides, dimethylaniline, pyridine, and the like.
The acid-addition salts of the bases herein described are the form in which the bases are most conveniently prepared for use and are the full equivalents of the subject matter specifically claimed. The acid moieties or anions in these salt forms are in themselves neither novel nor critical and therefore can be any acid anion or acid-like substance capable of salt formation with the free base form of the compounds. The preferred type of salts are watersoluble pharmacologically-acceptable salts, that is, salts whose anions are relatively innocuous to the animal organisms in pharmacological doses of the salts, so that the beneficial physiological properties inherent in the free base are not vitiated by side effects ascribable to the anions; in other words, the latter do not substantially affect the pharmacological properties inherent in the cations. In practicing the invention, it has been found convenient to form the hydrochloride salt. However, other appropriate pharmacologically-acceptable salts within the scope of the invention are those derived from mineral acids such as hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfamic acid, and sulfuric acid; and organic acids such as acetic acid, citric acid, tartaric acid, lactic acid, methanesulfonic acid, ethanesulfonic acid, quinic acid and the like, giving the hydrobromide, hydroiodide, nitrate, phosphate, sulfamate, sulfate, acetate, citrate, tartrate, lactate, methanesulfonate, ethanesulfonate, and quinate, respectively.
Although pharmacologically-acceptable salts are preferred, those having toxic anions are also useful. All acid-addition salts are useful intermediates as sources of the free base form even if the particular salt per se is not desired as the final product, as for example when the salt is formed only for purposes of purification or identification, or when it is used as an. intermediate in preparing a pharmacologically-acceptable salt by ion-exchange procedures.
The compounds of Formulas Ia, b and Ha, I; have been shown to possess CNS. and cardiovascular activity as evidenced by gross overt changes induced by intravenous administration in mice in standard tests involving observations of psychomotor activity, reactivity to stimuli, and ability to perform normal, non-conditioned motor tasks, This activity indicates their usefulness as psychotropic agents.
The compounds can be prepared for use by dissolving under sterile conditions a salt form of the compounds in water (or an equivalent amount of a non-toxic acid if the free base is used), or in a physiologically compatible aqueous medium such as saline, and stored in ampoules for intramuscular injection. Alternatively, they can be incorporated in unit dosage form as tablets or capsules for oral administration either alone or in combination with suitable adjuvants such as calcium carbonate, starch, lactose, talc, magnesium stearate, gum acacia, and the like. Still further, the compounds can be formulated for oral administration in aqueous alcohol, glycol, or oil solutions or oil-water emulsions in the same manner as conventional medicinal substances are prepared.
The molecular structures of the compounds of our invention were assigned on the basis of study of their infrared, ultraviolet, and NMR spectra and their transformation products, and confirmed by the correspondence between calculated and found values for the elementary analyses for representative examples.
The following examples will further illustrate the invention without, however, limiting it thereto.
EXAMPLE 1 l0-hydroxy-8- 3-methyl-2-octyl -3 ,5 ,S-trimethyl- 1 ,2,3,4- tetrahydro-SH- 1 Jbenzopyrano [3,4-c] pyridine (A) 10 hydroxy 5 oxo-3-methyl-8-(3-methyl-2-octyl- 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4 c]pyridine.--1 methyl 3 carbethoxy 4 piperdione hydrochloride, (42 g., 0.19 mole) was added in portions to 27.8 g. (0.12 mole) of 5-(3-methyl-2-octyl)resorcinol with stirring, and 48 ml. of concentrated sulfuric acid was then added dropwise to the mixture at room temperature. The mixture was then treated with 21 ml. of phosphorus oxychloride, stirred at room temperature for seventyeight hours, neutralized with aqueous potassium bicarbonate, and the product extracted into chloroform. The organic extracts were washed first with bicarbonate solution and then with water, dried over anhydrous sodium sulfate, and taken to dryness. The crude product (44 g.) was extracted with five 350 ml. portions of boiling acetonitrile, and from the fifth extract there was obtained 7.3 g. of 10 hydroxy-5-oxo-3-methyl-8-(3-methyl-2-octyl)- 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]-pyridine, M.P. 169-173 C.
'(B) 10 hydroxy 8 (3 methyl 2 octyl) 3,5,5- trimethyl 1, 2,3,4 tetrahydro 5H [1]benzopyrano- [3,4-c]pyridine.-A solution of 3.5 g. (0.01 mole) of 10- hydroxy 5 oxo 3 methyl 8 (3 methyl-2-octyl)- 1,2,3,4 tetrahydro 5I-I-[1]benzopyrano[3,4-c]pyridine, dissolved in 65 ml. of pyridine, was added dropwise to a solution of 0.1 mole of methyl magnesium iodide in ml. of anisole. When addition was complete, the mixture was stirred at 30-45 C. for about eight hours, cooled, and the excess Grignard reagent decomposed with 100 ml. of water. The mixture was then acidified with 300 ml. of 4 N sulfuric acid, and steam distilled to remove the anisole. The aqueous residue was then basified by the addition of solid sodium carbonate, and the pyridine removed by steam distillation. The solid which separated from the cooled reaction mixture was collected and dried giving 3.36 g. of the product in free base form. The latter was converted to the hydrochloride salt in ethyl acetate and recrystallized from acetonitrile giving 1.4 g. of 10-hydroxy-8-(3-methyl-2-octyl)-3,5,5-trimethyl- 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c] pyridine hydrochloride, M.P. 281-283 C.
Analysis.Calcd. for C H NO HCI (percent): C, 70.65; H, 9.39; N, 3.43. Found (percent): C, 71.07; H, 9.45; N, 3.42.
EXAMPLE 2 5 ,5 -dimethyl-1 0-hydroxy-8- 3 methyl-2-octyl- 1 ,2,3 ,4-tetrahydro-5H-[11benzopyrano [3 ,4-c] pyridine (A) 3 benzyl 10 hydroxy 8 (3 methyl 2- octyl) 5 oxo l,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine hydrochloride-1 benzyl 3- carbethoxy 4 piperidone hydrochloride, (11 g., 0.037 mole) was added in portions to 10.2 g. (0.041 mole) of 5-(3-methyl-2-octyl)resorcinol with stirring, and the mixture was then treated dropwise with cooling with 22 ml. of concentrated sulfuric acid. When addition was complete, 6 ml. of phosphorus oxychloride was added all at once, and the mixture stirred for sixteen hours at room temperature. Isolation of the product in the form of its hydrochloride salt and recrystallization from acetonitrile gave 6.5 g. of 3-benzyl-10-hydroxy-8-(3-methyl-2-octyl)- 5 oxo 1,2,3,4 tetrahydro 5H [l]benzopyrano- [3,4-c] pyridine hydrochloride, M.P. 236-240 C.
Analysis.Calcd. for C H No .HCl (percent): C, 71.55; H, 7.50; N, 2.97. Found (percent): C, 71.29; H, 7.74; N, 2.96.
(B) 3 benzyl 5,5 dimethyl 10 hydroxy-8-(3- methyl 2 octyl) 1,2,3,4 -tetrahydro 5H [l]benzopyrano[3,4-c] pyridine hydrochloride was prepared from 11.5 g. (0.026 mole) of 3-benzyl-10-hydroxy-8-(3-methyl- 2-octyl)-5-oxo-1,2,3,4-tetrahydro 5H [l]benzopyrano- [3,4-c]pyridine hydrochloride and 0.24 mole of methyl magnesium iodide in anisole using the procedure described above in Example 1-B. The crude product, isolated in the form of the hydrochloride salt, was recrystallized from ethyl acetate giving 2.9 g. of 3-benzyl 5,5- dimethyl-l-hydroxy-8-(3-metl1yl-2-octyl) 1,2,3,4 tetrahydro H [1]benzopyrano[3,4-c]pyridine hydrochloride, M.P. 149152 C.
Analysis.-Calcd. for C H NO .HCl (percent): C, 74.43; H, 8.74; N, 2.89. Found (percent): C, 73.56; H, 8.89; N, 2.83.
(C) 5,5 dimethyl hydroxy 8 (3 methyl-2- octyl 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]- pyridine.A solution of 10 g. (0.024 mole) of 3-benzyl- 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl- 1,2,3,4-tetrahydro 5H [l]benzopyrano[3,4-c] pyridine, dissolved in 150 ml. of absolute ethanol and 30 ml. of glacial acetic acid, was reduced with hydrogen at 45.5 pounds p.s.i. over 0.7 g. of a 10% palladium-on-charcoal catalyst. When reduction was complete, the solution was filtered from the catalyst, the filtrate evaporated to dryness, and the residue taken into chloroform and washed with aqueous potassium bicarbonate. The organic layer was then washed with water, dried over sodium sulfate, evaporated to dryness, and the red solid residue recrystallized once from acetonitrile and once from benzene to give 2.6 g. of 5,5-dimethyl-10-hydroxy-8-(3-methyl- 2 octyl) 1,2,3,4 tetrahydro 5H [l]benzopyrano- [3,4-c]pyridine, M.P. 168-170 C.
Analysis.--Calcd. for C H NO (percent): C, 77.26; H, 9.87; N, 3.92. Found (percent): C, 77.32; H, 10.06; N, 4.14.
(D) 5,5 dimethyl 10 hydroxy 8 (3 methyl-2- octyl) 3 (2 pyroynyl) 1,2,3,4 tetrahydro 5H- [l]benzopyrano [3,4-c]pyridine hydrochloride.-A mixture of 1.6 g. (0.004 mole) of 5,5-dimethyl-10-hydroxy-8- (3-methyl-2-octyl)-l,2,3,4 tetrahydro 5H [l]benzopyrano[3,4-c] pyridine, 0.52 g. (0.004 mole) of 3-bromol-propyne, 0.6 g. (0.006 mole) of anhydrous sodium carbonate, 0.1 g. of sodium iodide, and 30 ml. of absolute ethanol was stirred and refluxed under nitrogen for sixteen hours, cooled, filtered, and the filtrate evaporated to dryness. The red gummy residue was extracted with petroleum ether (B.P. 30-60" C.), the extracts concentrated to a small volume, filtered to remove about 300 mg. of a pink solid, and the filtrate evaporated to dryness. The resulting residue was taken into ether, the solution saturated with anhydrous hydrogen chloride, diluted with petroeum ether, and cooled to give 372 mg. of 5,5-dimethyl 10 hydroxy 8 (3 methyl 2 octyl)-3-(2- propynyl) 1,2,3,4 tetrahydro 5H [l]benzopyrano- [3,4-c]pyridine hydrochloride, M.P. 120l25 C.
AnaIysis.Calcd. for C H NO .HCl (percent): C, 72.28; H, 8.86; N, 3.24. Found (percent): C, 71.91; H, 8.43; N, 3.19.
EXAMPLE 3 3 allyl-5,5-dimethyl 10 hydroxy-8-(3-methyl-2-octyl)- 1,2,3,4 tetrahydro-SH-[l ]benzopyrano-[3,4-c1pyridine hydrochloride A mixture of 1.6 g. (0.004 mole) of 5,5-dimethyl-10- hydroxy-8-(3-methyl-2-octyl) -1,2,3,4-tetrahydr0-5H 1] benzopyrano[3,4-c]pyridine, 0.51 g. (0.004 mole) of 3- bromo-l-propene, 0.6 g. (0.006 mole) of anhydrous sodium carbonate, and 30 ml. of absolute ethanol was stirred and refluxed under nitrogen for sixteen hours, cooled, filtered, and the filtrate evaporated to dryness. The residue was taken into petroleum ether (B.P. 3060 C.), filtered, and the filtrate saturated with anhydrous hydrogen chloride to give a yellow gummy precipitate which was recrystallized from a petroleum ether-ethyl acetate mixture giving 0.54 g. of 3-allyl-5,5-dimethyl-lO-hydroxy- 8-(3-rnethyl-2-octyl) 1,2,3,4 tetrahydro-5H-[1]benzopyrano[3,4-c]pyridine hydrochloride, M.P. 2082l0 C.
Analysis.Calcd. for C H NO .HC1 (percent): C, 71.94; H, 9.29; N, 3.22. Found (percent): C, 72.08; H, 9.31; N, 3.04.
EXAMPLE 4 3 (trans-3-chloroallyl)-5,5-dimethyl-l0-hydroxy-8-(3- methyl-2-octyl 1,2,3,4 tetrahydro-5H[l]benzoypyrano- [3,4-c]pyridine hydrochloride was prepared from 1.6 g. (0.004 mole) of 5,5-dimethyl-l0-hydroxy-8-(3-methyl-2- octyl)-1,2,3,4-tetrahydro-5H-[ l]benzopyrano[3,4 c]pyridine, 0.48 g. (0.004 mole) of trans-1,3-dichloro-l-propene, 0.6 g. (0.006 mole) of anhydrous sodium carbonate, and 30 ml. of absolute ethanol using the manipulative procedure described above in Example 3. The crude product was isolated in the form of its hydrochloride salt, and the latter recrystallized once from a petroleum ether/ ethyl acetate mixture, and once from an ethyl acetate/ ethanol mixture giving 0.31 g. of 3-(trans-3-chloroallyl)- 5,5-dimethyl-l0-hydroxy 8 (3-methyl-2-octyl)-1,2,3,4- tetrahydro-SH- l benzopyrano 3,4-c] pyridine hydrochloride, M.P. 250-253 C.
Analysis.Calcd. tor C H ClNO .HCl (percent): C, 66.66; H, 8.39; N, 2.99. Found (percent): C, 66.41; H, 8.52; N, 2.88.
EXAMPLE 5 10-hydroxy-3-(Z-propynyl)-5,5,8-trimethyl-1,2,3,4- tetrahydro-5H-[ 1]benzopyrano 3,4-c] pyridine (A) 3-benzyl-10-hydroxy-8-methyl-5-oxo-1,2,3,4-tetratetrahydro-SH-[1]benzopyrano[3,4 c] pyridine.1-benzyl-3-carbethoxy 4 piperidone hydrochloride, (104 g., 0.33 mole) was mixed with g. (0.4 mole) of S-methylresorcinol, and the mixture treated dropwise over a period of one hour with 160 ml. of concentrated sulfuric acid. Phosphorus oxychloride ml.) was then added all at once, and the mixture stirred at room temperature for sixteen hours. Isolation of the product according to the procedure described above in Example 1-A afforded 0.6 g. of 3-benzyl-10-hydroxy-8-methyl-5-oxo-1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c]pyridine, M.P. 222- 224 C.
AnaIysis.Calcd. for C H NO (percent): C, 74.74; H, 5.96; N, 4.36. Found (percent): C, 74.58; H, 5.86; N, 4.29.
(B) 10-hydroxy-8-methyl-5-oxo-1,2,3,4-tetrahydro-5H [1]benzopyrano[3,4-c]pyridine was prepared by catalytic debenzylation of 2 g. (0.006 mole) of 3-benzyl-10-hydroxy-8-methyl-5-oxo 1,2,3,4 tetrahydro-5H-[11benzopyrano[3,4-c]pyridine in ml. of glacial acetic acid and 50 ml. of absolute ethanol under 54 pounds p.s.i. of hydrogen over 0.5 g. of 10% palladium-on-charcoal using the manipulative procedure described above in Example 2-C. Recrystallization of the crude product from ethanol afforded 0.1 g. of 10-hydroxy-8-methyl-5-oxol,2,3,4-tetrahydro 5H [1]benzoyprano[3,4-c]pyridine, M.P. 250-253" C.
Analysis.Calcd. for C H NO (percent): C, 67.52; H, 5.67; N, 6.06. Found (percent): C, 67.24; H, 5.71; N, 6.04.
(C) l0-hydroxy-8-methyl-5-ox0-3-(2-propynl)l,2,3,4- tetrahydro-5H-[l]benzopyrano[3,4 c]pyridine was prepared from 2.9 g. (0.01 mole) of 10hydroxy-8-methyl- 5-oxo-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4 c]pyridine, 2.1 g. (0.02 mole) of anhydrous sodium carbonate, and 1.19 g. (0.01 mole) of 3-bromo-1-propyne in 175 ml. of absolute ethanol using the manipulative procedure described above in Example 3. The crude product was recrystallized from acetonitrile to give 0.14 g. of -hydroxy-8-methyl-5-oxo-3-(2-propyuyl)-1,2,3,4-tetrahydro-5H[1]benzopyrano-[3,4 c]pyridine, M.P. 197- 200 C.
Analysis.Calcd. for C H NO (percent): C, 71.36; H, 5.61; N, 5.20. Found (percent): C, 71.14; H, 5.93; N, 5.14.
(D) 10-hydroxy-3-(2-propynyl)-5,5,8-trimethyl-1,2,3,4- tetrahydro-5H-[ 1 benzopyrano 3,4-c] pyridine is prepared by reacting 10-hydroxy-8-methyl-5-oXo-3-(2 propynyl)- 1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4 c]pyridine with methyl magnesium iodide in anisole according to the manipulative procedure described above in Example EXAMPLE -6 3-benzyl-lO-hydroxy 5,5,8 trimethyl-l,2,3,4-tetrahydro 5H [ljbenzopyrano[3,4-c]pyridine was prepared from 15.6 g. (0.048 mole) of 3-benzy1-l0-hydroxy-8- methyl-S-oxo 1,2,3,4 tetrahydro-5H [lj lbenzopyrano- [3,4-c]pyridine and 0.5 mole of methyl magnesium bromide in 350 ml. of anisole, and 120 ml. of pyridine using the manipulative procedure described above in -Example 1-B. The crude product was recrystallized from acetonitrile to give 4.0 g. of 3-benzyl-l0-hydroxy-5,5,8- trimethyl-1,2,3,4-tetrahydro 5H [1]benzoyprano[3,4-c] pyridine, M.P. 206--8 C.
Analysis.Calcd. for C H NO (percent): C, 78.77; H, 7.51; N, 4.18. Found (percent): C, 79.15; H, 7.36; N, 4.28.
EXAMPLE 7 5,5 dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-3-(2-propynyl) -1,2,3,4-tetrahydro-5H-[l]-benzopyrano[3,4 c] pyridine hydrochloride (A) 10-hydroxy-8-(3-methyl 2 octyl)-5-oxo-1,2,3,4- tetrahydro-5H-[1]benzopyrano[3,4 c]pyridine was prepared by catalytic debenzylation of 3-benzyl-10-hydroxy- 8 (3-methy1-2-octyl)-5-oxo 1,2,3,4 tetrahydro-SH-[l] benzoypyrano[3,4-c]pyridine in 200 ml. of absolute ethanol and 20 ml. of glacial acetic acid under 50 pounds p.s.i. of hydrogen over 1 g. of a 10% palladium-on-charcoal catalyst using the manipulative procedure described above in Example 2-C. The crude product was recrystallized twice from acetonitrile giving 1.9 g. of 10-hydr0xy- 8-(3-methyl-2-octyl)-5-oxo 1,2,3,4 tetrahydro-SH-[l] benzopyrano[3,4-c]pyridine, M.P. 177-179" C.
Analysis.Calcd. for C H NO (percent): C, 73.43; H, 8.51; N, 4.08. Found (percent): C, 73.06 H, 8.47; N, 4.23.
10-hydroxy-8-(3-methyl 2 octyl)-S-oxo-1,2,3,4-tetrahydro-5H-[1]benzopyran0[3,4-c1pyridine was also prepared by reaction of 5.8 g. (0.025 mole) of 3-carbethoxy- 4-piperidone hydrochloride with 5.9 g. (0.025 mole) of 5-(3-methyl-2-octyl)-resorcinol in 11.5 ml. of concentrated sulfuric acid and 4.5 ml. of phosphorus oxychloride using the manipulative procedure described above in Example 1-A. Recrystallization of the crude product from acetonitrile afforded 0.75 g. of 10-hydroxy-8-(3- methyl-2-octyl)-5-oxo 1,2,3,4 tetrahydro-5H-[11benzopyrano[3,4-c]pyridine, M.P. 179-181" C.
(B) 10 hydroxy 8 (3 methyl 2 octyl) 5 0x0- 3 (2 propynyl) 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4c]pyridine hydrochloride was prepared by reacting of 3.4 g. (0.01 mole) of 10-hydroxy-8-(3-methyl- 2-octyl) 5 oxo 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4-c]pyridine with 1.18 g. (0.01 mole) of 3-bromo-l-propyne in 175 ml. of absolute ethanol in the pres ence of 2.1 g. (0.02 mole) of anhydrous sodium carbonate using the manipulative procedure described above in Example 3. The crude product was isolated in the form of its hydrochloride salt and the latter recrystallized from 10 ethyl acetate giving 0.67 g. of 10-hydroxy-8-(3-methyl-2- octyl) 5 oxo 3 (2 propynyl) 1,2,3,4 tetrahydro- 5H [1]benzopyrano[3,4-c]pyridine hydrochloride, M.P. 132-135 C.
Analysis.Calcd. for C H NO .HCl (percent): C, 68.97; H, 7.71; N, 3.35. Found (percent): C, 68.86; H, 7.79; N, 3.37.
(C) 5,5 dimethyl 10 hydroxy 8 (3 methyl 2- octyl) 3 (2 propynyl) 1,2,3,4 tetrahydro 5H- [1]benzopyrano[3,4-c] pyridine hydrochloride can be prepared by reaction of 10-hydroxy-8-(3-methyl-2-octyl)-5- oxo 3 (2 propynyl) 1,2,3,4 tetrahydro 5H [1] benzopyrano[3,4-c]pyridine hydrochloride with methyl magnesium iodide in anisole, using the manipulative procedure described above in Example 1-B.
EXAMPLE 8 5,5 di (1 hexyl) 10 hydroxy 3 methyl 8 -(3- methyl 2 octyl) 1,2,3,4 tetrahydro 5H [1] benzopyrano[3,4-c]pyridine Following a procedure similar to that described in Example 1-B hereinabove, 10 hydroxy 3 methyl 8- (3-methyl 2 octyl) 1,2,3,4 tetrahydro 5H [l] benzopyrano[3,4-c]pyridine is reacted with n-hexyl magnesium bromide in anisole to give 5,5-di-(1-hexyl)-10-hydroxy 3 methyl 8 (3 methyl 2 octyl) 1,2,3,4- tetrahydro 5H [1]benzopyrano[3,4-c]pyridine.
EXAMPLE 9 3 cinnamyl 5,5 dimethyl 10 hydroxy 8 (3- methyl 2 octyl 1,2,3,4 tetrahydro 5H [l] benzopyrano [3 ,4-c] pyridine Following a procedure similar to that described in Example 3, 5,5 dimethyl 10 hydroxy 8 (3-methyl-2- octyl) 1,2,3,4 tetrahydro 5H [1]benZopyrano[3, 4-c]pyridine is reacted with cinnamyl chloride in the presence of anhydrous sodium carbonate to give 3-cinnamyl 5,5 dimethyl 10 hydroxy 8 (3 methyl-2- octyl)-l,2,3,4 tetrahydro 5H [l]benzopyrano[3,4-c] pyridine.
EXAMPLE 10 3 acetyl 5,5 dimethyl 10 hydroxy 8 (3 methyl- 2 octyl) 1,2,3,4 tetrahydro 5H [1]benzopyrano [3,4-c]pyridine By reaction of 5,5-dimethyl-IO-hydroxy-S-(3-methyl-2- octyl) 1,2,3,4 tetrahydro 5H [1]benzopyrano[3, 4-c]pyridine with an equimolar amount of acetyl chloride in, for example, a benzene solution, in the presence of triethylamine, there can be obtained 3-acetyl-5,5dimethyl- 10-hydroxy 8 (3 methyl 2 octyl) 1,2,3,4 tetrahydro-SH- l benzopyrano 3,4-c] pyridine.
EXAMPLE 11 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 phenylacetyl 1,2,3,4 tetrahydro 5H [1]benzo pyrano [3 ,4-c] pyridine By reaction of 5,5 dimethyl 10 hydroxy 8 (3- methyl 2 octyl) 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine with phenylacetyl chloride in the presence of pyridine in a benzene solution, there can be obtained 5,5 dimethyl 10 hydroxy 8 (3 methyl-2- octyl) 3 phenylacetyl l,2,3,4 -tetrahydro 5H [l] benzopyrano[3,4-c]pyridine.
EXAMPLE 12 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 (2 phenylethyl) 1,2,3,4 tetrahydro 5H [l] benzopyrano[3,4-c]pyridine By reduction of 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl) 3 phenylacetyl 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine with lithium aluminum hydride in tetrahydrofuran solution, there can be obtained 5,5 dimethyl 10 hydroxy 8 (3- methyl 2 octyl) 3 (2 phenylethyl) 1,2,3,4-tetrahydro H [1]benzopyrano[3,4-c1pyridine.
EXAMPLE 13 5,5 dimethyl hydroxy 8 (3 methyl 2 octyl)- 3 [2 (4 methylphenyl)ethyl] 1,2,3,4 tetrahydro- 5H- 1 benzopyrano 3,4-c] pyridine EXAMPLE 14 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 [3 (3,4 dimethoxyphenyl) propyl] 1,2,3,4- tetrahydro-5 H 1 benzopyrano 3,4-c] pyridine Following a procedure similar to that described in Example 3 hereinabove, 5 ,S-dimethyl 10 hydroxy 8 (3- methyl 2 octyl) 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine is reacted with 3-(3,4-dimethoxyphenyl)propyl bromide in absolute ethanol, in the presence of anhydrous sodium carbonate to give 5,5-dimethyl- 10 hydroxy 8 (3 methyl 2 octyl) 3 [3 (3,4- dimethoxyphenyl)propyl] l,2,3,4 tetrahydro 5H [1] benzopyrano[3,4-c] pyridine.
EXAMPLE 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 [1 (2,4,6 tribromophenyl)ethyl] 1,2,3,4 tetrahydro-SH- 1 benzopyrano 3,4-c pyridine Following a procedure similar to that described in Example 3 hereinabove, 5,5 dimethyl 10 hydroxy 8- (3 methyl 2 octyl) 1,2,3,4 tetrahydro 5H [1] benzopyrano[3,4-c]pyridine is reacted with 1-(2,4,6-tribromophenyl)ethyl bromide in the presence of anhydrous sodium carbonate to give 5,5-dimethyl 10 hydroxy- 8-(3 methyl 2 octyl) 3 [1 (2,4,6 tribromophenyl)ethyl] 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine.
EXAMPLE 16 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 [4 (4 nitrophenyl)butyl] l,2,3,4 tetrahydro- 5H-[1]benzopyrano[3 ,4-c] pyridine Following a procedure similar to that described in Example 3 hereinabove, 5,5 dimethyl 10 hydroxy 8- (3 methyl 2 octyl) 1,2,3,4 tetrahydro 5H [1] benzopyrano[3,4-c]pyridine is reacted with 4 (4 nitrophenyl)butyl bromide in the presence of anhydrous sodium carbonate to give 5 ,5 dimethyl 10 hydroxy 8 (3- methyl 2 octyl 3 [4 (4 nitrophenyl)butyl]- 1,2,3,4-tetrahydro-5H-[ 1]benzopyrano 3,4-c] pyridine.
EXAMPLE 17 5,5 dimethyl 10 hydroxy 8 (3-methy1-2-octyl)-3- [2 (4 methylmercaptophenyl)ethyl]-l,2,3,4-tetrahydro-5H-[ l benzopyrano[3,4-c] pyridine Following a procedure similar to that described in Example 3 hereinabove, 5,5 dimethyl 10-hydroxy-8-(3- methyl 2-octyl)-1,2,3,4-tetrahydro-5H-[ 1]benzopyrano- [3,4-c]pyridine is reacted with 2 (4-methylmercaptophenyl)ethyl bromide in the presence of anhydrous sodium carbonate to give 5,5 dimethyl 10-hydroxy-8-(3- methyl 2-octyl)-3-[2-(4-methyl-mercaptophenyl)ethyl]- 1,2,3,4-tetrahydro 5H [1]benz0pyrano-[3,4-c] pyridine.
EXAMPLE 18 5,5 dimethyl 10 hydroxy 8 (3 methy1-2-octyl)- 3 {3 [1 -(3,4-methylenedioxyphenyl)-1-buteny1] 1,2,3,4-tetrahydro-5H-[ l ]benzopyrano [3,4-c] pyridine Following a procedure similar to that described in Example 3 hereinabove, 5,5 dimethyl-10-hydroxy-8-(3- methyl 2-octyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano- [3,4-c]pyridine is reacted with 3 [1-(3,4-methylenedioxyphenyl)-1-butenyl] bromide in the presence of anhydrous sodium carbonate to give 5,5-dimethyl-10-hydroxy- 8 (3 methyl 2-octyl)-3-{3-[1-(3,4-methylenedioxyphenyl) 1 butenyl]}-1,2,3,4-tetrahydro-5H-[1]benzopyran0[3,4-c]pyridine.
EXAMPLE 19 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octy1) 3 {3-[1- (4 acetylaminophenyl) 1 butenyl]} 1,2,3,4 tetrahydro-5H-[ 1 benzopyrano 3,4-c] pyridine Following a procedure similar to that described in Example 3 hereinabove, 5,5 dimethyl l0-hydroxy-8-(3- methyl 2-octyl)-1,2,3,4-tetrahydro-5H-[ 1]benZopyrano- [3,4-c]pyridine is reacted with 3 [1 (4-acetylaminophenyl)-1-butenyl] bromide in the presence of anhydrous sodium carbonate to give 5,5-dimethyl-10-hydroxy-8-(3- methyl 2 octyl) 3-{3-[1-(4-acetylaminophenyl)-1- butenyl]} 1,2,3,4 tetrahydro 5H-[1]benzopyrano- [3,4-cJpyridine.
EXAMPLE 20 5,5 dimethyl 10 hydroxy 8 (3-methyl-2-octyl)-3- {4 [l (3-trifluoromethylphenyl)-1-butenyl]}-l,2,3,4- tetrahydro-SH- 1]benzopyrano [3,4-c] pyridine Following a procedure similar to that described in Example 3 hereinabove, 5,5 dimethyl 10-hydroxy-8-(3- methyl 2 octyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano [3,4-c]pyridine is reacted with 4-[1-(3-trifiuoromethylphenyl)-l-butenyl] bromide in the presence of anhydrous sodium carbonate to give 5,5-dimethyl-10-hydroxy-8-(3- methyl 2 octyl)-3-{4-[1-(3-trifiuoromethylphenyl)-1- butenyl]} 1,2,3,4 tetrahydro 5H-[l]benzopyrano[3,4- c] pyridine.
EXAMPLE 21 3 cyclopropylcarbonyl 5,5-dimethyl-10-hydroxy-8-(3- methyl 2 octyl) 1,2,3,4-tetrahydro-5H-[1]benzopyrano [3 ,4-c] pyridine Following a procedure similar to that described in Example 11 hereinabove, 5,5-dimethyl-10-hydroxy-8-(3- methyl 2-octyl)-1,2,3,4-tetrahydro-5H-[1]benzopyrano- [3,4 c]pyridine is reacted with cyclopropylcarbonyl chloride in benzene solution in the presence of pyridine to give 3 cyclopropylcarbonyl-5,S-dimethyl-10-hydroxy- 8 (3-methyl 2-octyl)-l,2,3,4-tetrahydro-5H-[l]benzopyrano [3,4-c] pyridine.
EXAMPLE 22 3 cyclopropylmethyl 5,5 dimethyl-10-hydroxy-8-(3- methyl 2 octyl) 1,2,3,4-tetrahydro-5H-[l]benzopyrano [3 ,4-c] pyridine Following a procedure similar to that described in Example 12 hereinabove, 3 cyclopropylcarbonyl-5,S-dimethyl l0 hydroxy 8 (3-methyl-2-octyl)-1,2,3,4- tetrahydro 5H [1] benzopyrano[3,4-c] pyridine is reduced with lithium aluminum hydride in tetrahydrofuran to give 3 cyclopropylmethyl-S,S-dimethyl-10-hydroxy-8- (3 methyl 2 octyl) 1,2,3,4-tetrahydro-5H-[l]benzopyrano[3,4-c] pyridine.
EXAMPLE 23 5,5 dimethyl 1O hydroxy 8 (3-methyl-2-octyl)-3- 3 phenyl 2 propynyl) 1,2,3,4-tetrahydro-5H[ 1]- benzopyrano-[3,4-c]pyridine Following a procedure similar to that described in Example 3 hereinabove, 5,5 dimethyl 1O hydroxy-8(3- EXAMPLE 24 10-acetoxy-8- 3-methyl-2-octyl -3,5,5-trimethyl-1 ,2,3,4- tetr ahydro-SH- l benzopyrano [3,4-c] pyridine By reacting 10 hydroxy-8-(3-methyl-2-octyl) -3,5,5-trimethyl 1,2,3,4 tetrahydro H-[l]benzopyrano[3,4-c] pyridine with acetic anhydride, there is obtained IO-acetoxy 8 (3-methyl-2-octyl)-3,5,5-trimethyl-1,2,3,4-tetrahydro-5H-[ 1] -benzopyrano [3,4-c] pyridine.
EXAMPLE 25 -methoxy-8-(3-methyl-2-octy1)-3,5,5-trimethyl-1,2,3,4 tetrahydro-5H-[ 1] -b enzopyrano 3 ,4-c] pyridine By reacting 10-hydroxy-8-(3-methyl-2-0ctyl)-3,5,5-trimethyl 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4- c] pyridine with methyl iodide in the presence of sodium ethoxide, there is obtained 10 methoxy-8-(3-methy1-2- octyl) 3,5,5 trimethyl 1,2,3,4 tetrahydro 5H [1]- benzopyrano[3,4-c] pyridine.
EXAMPLE 26 10 carbamyloxy 8 (3 methyl 2 octyl)-3,5,5-
trimethyl 1,2,3,4-tetrahydro 5H [1]benzopyrano- [3,4-c]pyridine By reacting 10-hydroxy-S-(3-methyl-2-octyl)-3,5,5-trimethyl 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4- c] pyridine with an equimolar amount of phosgene in the presence of dimethylaniline, and reacting the resulting chloroformate with liquid ammonia, there is obtained 10- carbamyloxy 8 (3 methyl 2- octyl)-3,5,5-'trimethyl- 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine.
EXAMPLE 27 10 (N methylcarbarnyloxy) 8 (3 methyl-2-octyl)- 3,5,5 trimethyl 1,2,3,4 tetrahydro-5H [1]benzopyrano[3,4-c]pyridine By reacting 10-hydroxy-8-(3-methy1-2-octyl)-3,5,5-trimethyl 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4- c] pyridine with an equimolar amount of phosgene in the presence of dimethylaniline, and reacting the resulting chloroformate 'with methylamine, there is obtained 10- (N-methylcarbamylox-y) 8 (3 methyl 2 octyl)- 3,5,5 trimethyl 1,2,3,4 tetrahydro 5H-[1]benzopyrano[3,4-c]pyridine.
'EXAMPLE 28 1O =(N,N dimethylcarbamyloxy 8 (3 methyl 2- octyl) 3,5,5 trimethyl 1,2,3,4 tetrahydro 5H- 1] benzopyrano 3,4-c] pyridine 8-(3-methyl-2-octyl)-10-phosphonyloxy-3,5,5 trimethyl- 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4 c]pyridine By reacting 10-hydroxy-8-(3-methyl-2-octyl)-3,5,5-trimethyl-1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4- c] pyridine with one molar equivalent amount of phosphorus oxychloride in toluene in the presence of pyridine, and reacting the resulting dichlorophosphinate with aqueous 14 potassium carbonate, there is obtained 8-(3-methyl-2- octyl)-10-phosphonyloxy 3,5,5 trimethyl l,2,3,4-tetrahydro-5I-l-[ 1 benzopyrano [3,4-c] pyridine.
EXAMPLE 30 10-hydroxy-8- (3 -methyl-2-octyl) -3 ,5 ,5 -trimethyl-5 H- [l]benzopyrano[3,4-c]piperidine By reducing 10-hydroXy-8-(3-methyl-2-octyl)-3,5,5-trimethyl 1,2,3,4 tetrahydro- 5H-[1]benzopyrano[3,4-c] pyridine with hydrogen in an ethanol solvent over a Raney nickel catalyst, there is obtained 10-hydroxy-8-(3-methyl- 2-octyl)-3,5,5-trimethyl-5H-[ l]benzopyrano [3,4 c]piperidine.
EXAMPLE 31 By reducing the compounds of Examples 2-B, 2C, 8, 10, 11, 12, 13, 14, 15, 17, 21, 22, 24, 25, 26, 27, 28, and 29 with hydrogen over a Raney nickel catalyst following the procedure described above in Example 30, there can be obtained the following respective compounds of Formula Ila:
(A) 3 -benzyl-5 ,5 -dimethyl- 1 O-hydroxy-S- 3-methyl-2- octyl)-5H-[1]benzopyrano[3,4-c]piperidine.
(B 5 ,5 -dimethyll O-hydroxy-S- (3-methyl-2-octyl) -5H- [1]benzopyrano[3,4-c1piperidine.
(C) 5 ,5 -dil-hexyl 10-hydroxy-3-methyl-8- (3-methyl- 2-octyl)-5H-[1]benzopyrano[3,4c]piperidine.
(D) 3 -acetyl-5 ,5 -dimethyl-1 O-hydroxy- 8- 3-methyl-2- octyl)-5H-[1]benzopyrano[3,4-c]piperidine.
(-E) 5 ,5 -dimethyl- 10-hydroxy-8- (3 -methyl-2-octyl -3- phenylacetyl-5H-[ 1]benzopyrano[3,4-c]piperidine.
(F) 5 ,5 -dimethyl-1 O-hydroxy- 8- (3 -methyl-2-octyl) -3- (2- phenylethyl)-5H-[1]benzopyrano[3,4-c]piperidine.
(G) 5 ,5 -dimethyl-10hydroXy-8- 3-methyl-2-octyl) -3- [2- (4-methylphenyl) ethyl] -5H-[ l]benzopyran0 3,4- c] piperidine.
(H) 5,5-dirnethyl-10-hydroxy-8- 3-methyl-2-octyl) -3- [3 (3 ,4-dimethoxyphenyl pro pyl] -5H- 1 benzopyrano- [3,4-c] piperidine.
(J) 5,5-dimethyl-10-hydroxy-S- 3-methyl-2-octyl) -3- [1- (2,4,6-tribromophenyl ethyl] -5H- 1 benzopyrano- [3,4-c] piperidine.
(K) 5 ,5 -dimethyl-1 O-hydroxy-S- 3 -methyl-2-octyl) -3- [2-(4-methylmercaptophenyl) ethyl] -5H- 1] benzopyrano 3,4-c] piperidine.
(L) 3 -cyclopropylcarb onyl-5, 5 -dimethyl- 1 O-hydroxy-S- (3-rnethyl-2-octyl) -5H-[ 1 benzopyrano [3 ,4-c] piperidine.
(M) 3-cyclopropylmethyl-5 ,5 -dimethyl- 1-0-hydroxy-8- (3-methyl-2-octyl)-5H-[1]benzopyrano[3,4-c] piperidine.
(N) l0-acetoxy-8- (3-methyl-2-octyl) -3,5,5-trimethyl- 5H-[1]benzopyrano[3,4-c]piperidine.
('0) 10-methoxy-8- 3 -methyl-2-octyl -3 ,5 ,5 -trimethyl- 5H-[1]benzopyrano[3,4-c]piperidine.
(P) IO-carbamyloxy-S- 3-methyl-2-octyl -3,5,5-
trimethyl-5H-[1]benzopyrano[3,4-c]piperidine.
(Q) 10- (N-methylcarb amyloxy -8- 3 -methyl-2-o ctyl 3,5 ,5-trimethyl-5H-[ 1 benzopyrano [3 ,4-c] piperidine.
(R) 1'0- (N,N-dimethylcarbamyloxy) -8- 3-methyl-2- octyl) -3,5 ,5 -trimethyl-5 H- 1 benzopyrano [3,4-c] piperidine.
(S) 8- 3-methyl-2-octyl 1 0ph0sphonyloxy-3,5 ,5
trimethyl-5H-[1]benzopyrano[3,4-c]piperidine.
EXAMPLE 32 3 -allyl-5,5-dimethy1-10-hydroxy-8-( 3 -methyl2-octyl) 5H-[1]benzopyrano[3 ,4-c] piperidine Following a procedure similar to that described in Example 3 hereinabove, 5,5-dimethyl-10-hydroxy-8-(3-methyl 2 octyl)-5H-[1]benzopyrano[3,4-c]piperidine is reacted with 3-bromo-1-propene in absolute ethanol in the presence of anhydrous sodium carbonate to give 3-allyl- 5,5 dimethyl 10 hydroxy-S-(3-methyl-2-octyl)-5H-[1] benzopyrano[3,4-c]piperidine.
1 5 EXAMPLE 33 3- (trans-3-chloroallyl) -5 ,5 -dimethyl- 1 -hydroXy-8- 3 methyl-2-octyl)-5H-[1]benzopyrano[3,4-c]piperidine Following a procedure similar to that described in Example 3 hereinabove, 5,5-dimethyl-10-hydroxy-8-(3-methyl 2 octyl)-5H-[1]benzopyrano[3,4-c]piperidine is reacted with trans-1,3-dichloro-1-propane in absolute ethanol in the presence of anhydrous sodium carbonate to give 3-(trans-3-chloroallyl)-5,5-dimethyl 1O hydroxy-8- (3-methyl-2-octyl)-5H-[1]benzopyrano[3,4-c]piperidine.
EXAMPLE 34 -hydroxy-3 (2-propynyl -5 ,5 ,S-trimethyl-S H- 1 benzopyrano [3 ,4-c] piperidine Following a procedure similar to that described in Example 3 hereinabove, 10-hydroxy-S,5,8-trimethyl-5H-[1] benzopyrano[3,4-c]pyridine is reacted with 3-bromo-1- propyne in absolute ethanol in the presence of anhydrous sodium carbonate to give 10-hydroxy-3-(2-propynyl)-5,5, 8-trimethyl-5H-[1]benzopyrano[3,4-c]piperidine.
EXAMPLE 35 5 ,5-dimethyll O-hydroxy-S- 3-methyl-2-octyl) -3- 2- propynyl)-SH-[1]benzopyrano[3 ,4-c1piperidine Following a procedure similar to that described in Example 3 hereinabove, 5,5-dimethyl-10-hydroxy-8-(3-methyl 2 octyl)-5H-[1]benzopyrano[3,4-c]piperidine is reacted with 3-bromo-l-propyne in absolute ethanol in the presence of anhydrous sodium carbonate to give 5,5-dimethyl 1O hydroxy 8 (3-methyl-2-octyl)-3-(2-propynyl)-5H-[1]benzopyrano[3,4-c]piperidine.
EXAMPLE 36 3-cinnamyl-5 ,5 -dimethyl- 10-hydroxy-8- 3-methyl-2- octyl) -5H- l benzopyrano [3,4-c] piperidine Following a procedure similar to that described in Example 3 hereinabove, 5,5-dimethyl-10-hydroxy-8-(3-methyl 2 octyl)-5H-[1]benzopyrano[3,4-c]piperidine is reacted with cinnamyl chloride in absolute ethanol in the presence of anhydrous sodium carbonate to give 3-cinnamyl-5,5 dimethyl 10 hydroxy-8-(3-methyl-2-octyl)- 5 H- l 'benzopyrano 3,4-c] piperidine.
EXAMPLE 37 5,5-dimethyl l0 hydroxy-8-(3-methyl-2-octyl)-3-[4-(4- nitrophenyl)butyl] 5H [1]benzopyrano[3,4-c]piperidine Following a procedure similar to that described in Example 3 hereinabove, 5,5-dimethyl-10-hydroxy-8-(3-methyl 2 octyl)-5H-[l1benzopyrano [3,4-c] piperidine is reacted with 4-(4-nitrophenyl)butyl bromide in absolute ethanol in the presence of anhydrous sodium carbonate to give 5,5-dimethyl-10-hydroxy-8-(3-methyl-2-octyl)-3- [4-(4-nitrophenyl)butyl] 5H [1]benzopyrano[3,4 c] piperidine.
EXAMPLE 38 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 {3 [l (3,4 methylenedioxyphenyl) 1 butenyl]} 5H [1]benzopyrano[3,4-c]piperidine Following a procedure similar to that described in Example 3 hereinabove, 5,5 dimethyl 10 hydroxy- 8 (3 methyl 2 octyl) 5H [1]benzopyrano[3,4-c] piperidine is reacted with 3 [1 (3,4 methylenedioxyphenyl) 1 butenyl] bromide in absolute ethanol in the presence of anhydrous sodium carbonate to give 5,5- dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 {3 [l (3,4 methylenedioxyphenyl) l butenyl]}- 5H-[1]benzopyrano[3,4-c]-piperidine.
16 EXAMPLE 39 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 {3 [1 (4 acetylaminophenyl) 1 butenyl]}- 5H-[1]benzopyrano[3 ,4-c] -piperidine Following a procedure similar to that described in EX- ample 3 hereinabove, 5,5 dimethyl 10 hydroxy 8- (3 methyl 2 octyl) 5H [1]benzopyrano[3,4-c] piperidine is reacted with 3 [1 (4 acetylaminophenyl)- l-butenyl] bromide in absolute ethanol in the presence of anhydrous sodium carbonate to give 5,5 dimethyl- 10 hydroxy 8 (3 methyl 2 octyl) 3 {3 [l- (4 acetylaminophenyl) 1 butenyl]} 5H [l]benzopyrano [3 ,4-c] piperidine.
EXAMPLE 40 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 {4 [1 (3 trifiuoromethylphenyl) 1 butenyl]}- 5H-[1]benzopyrano[3,4-c]piperidine EXAMPLE 41 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl)- 3 (3 phenyl 2 propynyl) 5H [1]benzopyrano [3,4-c1piperidine Following a procedure similar to that described in Example 3 hereinabove, 5,5 dimethyl 10 hydroxy 8 (3 methyl 2 octyl) 5H [l]benzopyrano[3,4-c] piperidine is reacted with 3 phenyl 2 propynyl bromide in absolute ethanol in the presence of anhydrous sodium carbonate to give 5,5 dimethyl 10 hydroxy- 8 (3- methyl 2 octyl) 3 (3 phenyl 2 propynyl)- 5H-[ 1 benzopyrano [3,4-c] piperidine.
EXAMPLE 42 3 benzyl 8 hydroxy 10 methyl 5 oxo 1,2,3-4- tetrahydro 5H [1]benzopyrano[3,4-c]pyridine is obtained by reaction of 1 benzyl 3 carbethoxy 4- piperidone with S-methylresorcinol according to the procedure described above in Example 5-A.
EXAMPLE 43 8 hydroxy 1O methyl 5 oxo 1,2,3,4 tetrahydro- 5H [1]benz0pyrano[3,4-c] pyridine is prepared by catalytic debenzylation of 3 benzyl 8 hydroxy 10- methyl 5 oxo 1,2,3,4 tetrahydro 5H [1]benzopyran0[3,4-c]pyridine according to the procedure described above in Example 5-B.
EXAMPLE 44 8 hydroxy 5,5,10 trimethyl 1,2,3,4 tetrahydro- 5H [1]benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy 10 methyl 5 oxo 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine with methyl magnesium iodide according to the procedure described above in Example 6,.
EXAMPLE 45 8 hydroxy 3,5,5,10 tetramethyl 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c] pyridine is prepared by reaction of 8 hydroxy 10 methyl 5,5 dimethyl- 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4-c]pyridine with methyl bromide in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
l 7 EXAMPLE 46 3 benzyl 8 hydroxy 5,5,10 trirnethyl l,2,3,4- tetrahydro 5H [1] benzopyrano[3,4-c]pyridine is prepared by reacting 3 benzyl 8 hydroxy 10 methyl- 5 oxo 1,2,3,4 tetrahydro 5H [1]benzopyrano [3,4-c] pyridine with methyl magnesium bromide in anisole according to the procedure described above in Example 6.
EXAMPLE 47 8 hydroxy 1O methyl 5,5 dihexyl 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy 10 methyl 5 oxo l,2,3,4- tetrahydro 5H [l]benzopyrano[3,4 c]pyridine with n-hexyl magnesium bromide according to the procedure described above in Example 6.
EXAMPLE 48 3 cinnamyl 8 hydroxy 5,5,10 trirnethyl l,2,3,4- tetrahydro 5H [1]benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy 5,5,10 trirnethyl l,2,3,4- tetrahydro 5H [l]benzopyrano[3,4 cJpyridine with cinnamyl chloride in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EXAMPLE 49 3 acetyl 8 hydroxy 5,5,10 trirnethyl l,2,3,4- tetrahydro 5H [1]benzopyrano[3,4-c]pyridine is pre pared by reacting 8-hydroXy-5,5,IO-trimethyl-l,2,3,4-tetrahydro 5H [1]benzopyrano[3,4 c]pyridine with an equimolar amount of acetyl chloride in a benzene solution and in the presence of triethylamine according to the procedure described above in Example 10.
EXAMPLE 50 3 phenylacetyl 8 hydroxy 5,5,10 trimethyl 1,2, 3,4 tetrahydro -5H [l]benzopyrano[3,4-c1pyridine is prepared by reacting 8 hydroxy 5,5,10 trimethyl- 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine with phenylacetyl chloride in a benzene solution and in the presence of pyridine according to the procedure described above in Example 11.
EXAMPLE 51 3 (2 phenylethyl) 8 hydroxy 5,5,10 trimethyl- 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine is prepared by reacting 3 phenylacetyl 8 hydroxy- 5,5,10 trimethyl 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4-c] pyridine with lithium aluminum hydride in a tetrahydrofuran solution according to the procedure described above in Example. 12.
EXAMPLE 52 3 [2 (4 methylphenyl)ethyl] 8 hydroxy 5,5,10- trimethyl 1,2,3,4 tetrahydro 5H [1]benzopyrano [3,4-c] pyridine is prepared by reacting 8 hydroxy 5,5, 10 trimethyl 1,2,3,4 tetrahydro 5H [1]benzopyrano [3,4-] pyridine with 2 (4 methylphenyl)ethyl bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EXAMPLE 53 3 [3 (3,4 dimethoxyphenyl)propyl] 8 hydroxy- 5,5,10 trimethyl 1,2,3,4 tetrahydro H [l]benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy- 5,5,10 trimethyl 1,2,3,4 tetrahydro 5H [l]benzopyrano[3,4-c]pyridine with 3 (3,4 dimethoxyphenyl) propyl bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EXAMPLE 54 3-[1-(2,4,6-tribromophenyl)ethyl] 8 hydoxy-5,5,10- trimethyl-1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c]
pyridine is prepared by reacting 8-hydroxy-5,5,10-trimethyl-1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c]pyridine with 1-(2,4,6-tribromophenyl)ethyl bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EXAMPLE 55 3-[4-(4 nitropheny1)butyl] 8 hydroxy-5,5,10-trimethyl-l,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c] pyridine is prepared by reacting 8 hydroxy-5,5,10-trimethyl-1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c] pyridine with 4-(4-nitrophenyl)butyl bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EPQAMPLE 5 6 3-{3-[1-(3,4-methylenedioxyphenyl) 1 butenyl]}-8- hydroxy-5,5,IO-trimethyl 1,2,3,4 tetrahydro 5H [1] benzopyrano[3,4-c1pyridine is prepared by reacting 8-hydroxy-5,5,l0-trimethyl-1,2,3,4-tetrahydro 5H [1]benzopyrano[3,4-c]-pyridine with 3 [3,4 methylenedioxyphenyl)-1-butenyl1bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EXAMPLE 5 8 3 {3-[1-(4-acetylaminophenyl)-l-butenyl]} 8 hydroxy-5,5,10-trimethyl 1,2,3,4 tetrahydro-5H-[11benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy-5,5,10-trirnethyl 1,2,3,4 tetrahydro-5H-[11benzopyrano[3,4-c]pyridine with 3 [1 (4-acetylaminophenyl) 1 butenylJbromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EXAMPLE 5 9 3-{4-[1-(3-trifluoromethylphenyl) 1 butenyl]}-8-hydroxy-5,5,10-trimethyl 1,2,3,4 tetrahydro-5H-[11benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy-5,5,10-trimethyl 1,2,3,4 tetrahydro-5H-[11benzopyrano[3,4-c]pyridine With 4 [1-(3-trifiuoromethylphenyl)-1-butenyl]bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EXAMPLE 60 3-cyclopropylcarbonyl 8 hydroxy-5,5,IO-tri-methyl- 1,2,3,4 tetrahydro 5H-[1]benzopyrano[3,4-c]pyridine is prepared by reacting 8-hydroxy-5,5,10-trimethyl-1,2,3,4- tetrahydro 5H [1]benzopyrano[3,4-c] pyridine With cyclopropylcarbonyl chloride in a benzene solution and in the presence of pyridine according to the procedure described above in Example 21.
EXAMPLE 61 3-cyclopropylmethyl 8 hydroxy-5,5,l0-trimethyl-l,2, 3,4-tetrahydro 5H [l]benzopyrano[3,4-c]pyridine is prepared by reducing 3 cyclopropylcarbonyl-8-hydroxy- 5,5,10-trimethyl 1,2,3,4 tetrahydro-5H-[l1benzopyrano [3,4-c] pyridine with lithium aluminum hydride according to the procedure described above in Example 22.
EXAMPLE 62 3-(3-phenyl 2 propynyl)-8-hydroxy-5,5,IO-trimethyll,2,3,4-tetrahydro 5H [l]benzopyrano[3,4-c]pyridine is prepared by reacting 8-hydroxy-5,5,10-trimethyl-1,2,3,4-
19 tetrahydro 5H [l]benzopyrano[3,4-c1pyridine with 3- phenyl-2-propynyl bromide in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EXAMPLE 63 3 allyl-8-hydroxy-5,5,IO-trimethyl l,2,3,4 tetrahydro 5H [l]-benzopyrano[3,4-c1pyridine is prepared by reacting 8-hydroxy-5,5,lO-trimethyl l,2,3,4 tetrahydro- SH-[1]benzopyrano[3,4-c]pyridine with 3 bromo-l-propene in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 3.
EXAMPLE 64 3-(2-propynyl) 8 hydroxy-5,5,lO-trimethyl-l,2,3,4- tetrahydro 5H [l]benzopyran[3,4-c]pyridine is prepared by reacting 8-hydroxy-5,5,IO-trimethyl-1,2,3,4-tetrahydro H [l]benzopyrano[3,4-c]pyridine with 3-brorno-l-propyne in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 2-D.
EXAMPLE 65 3-(trans 3 chloroallyl)-8-hydroxy-5,5,IO-trimethyl- 1,2,3,4-tetrahydro 5H [l]benzopyrano[3,4-c] pyridine is prepared by reacting 8-hydroxy-5,5,lO-trimethyl-1,2,3,4- tetrahydro-5H-[l]benzopyrano[3,4-c] pyridine with trans- 1,3-dichloro-1-propene in absolute ethanol in the presence of anhydrous sodium carbonate according to the procedure described above in Example 4.
EXAMPLE 66 S-acetoxy 3,5,5,10 tetramethyl-1,2,3,4-tetrahydro- 5l-I-[l]benzopyrano[3,4-c]pyridine is prepared by reacting 8-hydroxy-3,5,5,IO-tetramethyl 1,2,3,4 tetrahydro- 5H-[l]bcnzopyrano[3,4-c] pyridine with acetic anhydride according to the procedure described above in Example 24.
EXAMPLE 67 8 methoxy-3,5,5,IO-tetramethyl 1,2,3,4 tetrahydro- 5H-[l]benzopyrano[3,4-c] pyridine is prepared by reacting 8-hydroxy-3,5,5,IO-tetramethyl 1,2,3,4 tetrahydro- 5H-[l]benzopyrano[3,4-c]pyridine with methyl iodide in the presence of sodium ethoxide according to the procedure described above in Example 25.
EXAMPLE 68 S-carbarnyloxy 3,5,5,l0 tetramethyl-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridine is prepared by reacting 8-hydroxy 3,5,5,l0 tetramethyl-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridine with an equimolar amount of phosgene in the presence of dimethylaniline, and reacting the resulting chlorotormate with liquid ammonia according to the procedure described above in Example 26.
EXAMPLE 69 8-(N-methylcarbamyloxy) 3,5,5,l0 tetra1nethyl-l,2, 3,4-tetrahydro 5H [l]benzopyrano[3,4-c]pyridine is prepared by reacting 8-hydroxy-3,5,5,l0-tetramethyl-1,2, 3,4-tetrahydro 5H [l]benzopyrano[3,4-c]pyridine with an equimolar amount of phosgene in the presence of dimethylaniline, and reacting the resulting chloroformate with methylamine according to the procedure described above in Example 27.
EXAMPLE 7O 8 (N,N dimethylcarbamyloxy) 3,5,5,l0 tetramethyl 1,2,3,4 tetrahydro 5H [l]benzopyrano[3, 4-c]pyridine is prepared by reacting 8-hydroxy-3,5,5,10- tetramethyl 1,2,3,4 tetrahydro 5H[l]benzopyrano [3,4-c1pyridine with an equimolar amount of phosgene in the presence of dimethylaniline, and reacting the resulting chloroformate with dimethylamine according to the procedure described above in Example 28.
20 EXAMPLE 71 8 phosphonyloxy 3,5,5,10 tetramethyl 1,2,3,4- tetrahydro 5H [l] benzopyrano[3,4-c]pyridine is prepared by reacting 8 hydroxy 3,5,5,10 tetramethyl- 1,2,3,4 tetrahydro 5H [1]benzopyrano [3,4-c]pyridine with one molar amount of phosphorus oxychloride in toluene in the presence of pyridine, and reacting the resulting dichlorophosphinate with aqueous potassium carbonate according to the procedure described above in Example 29.
EXAMPLE 72 By reducing the compounds of Examples 4471 With hydrogen over a Raney nickel catalyst, following the procedure described above in Example 30, there can be obtained the following respective compounds of Formula IIb:
(A) 8-hydroxy-5 ,5 l0-trimethyl-5H- l benzopyrano [3 ,4-c] piperidine.
(B) 8-hydroxy-3,5 ,5 ,lO-tetramethyl-SH- 1] benzopyrano 3,4-c] piperidine.
(C) 3-b enzyl-8-hydroxy-5 ,5 1 O-trimethyl-S H- 1 benzopyrano [3,4-c] piperidine.
(D) S-hydroxy- 10-methyl-5 ,S-dihexyl-SH- 1] benzopyrano [3 ,4-c] piperidine.
(E) 3 -cinnamyl-8-hydr0xy-5,5,IO-trimethyl-SH-[1] benzopyrano [3 ,4-c] piperidine.
(F) 3-acetyl-8-hydroxy-5,5,10-trimethyl-5H-[1] benzopyrano- [3,4-c] piperidine.
(G) 3-phenylacetyl-8-hydroxy-5 ,5 l O-trimethyl-S H- l benzopyrano- [3 ,4-c] piperidine.
(H) 3 2-phenylethyl S-hydroxy-S ,5 1 O-trimethyl- 5H[ 1 ]benzopyrano [3,4-c1piperidine.
(J 3- [2-(4-methylphenyl)ethyl] -8-hydr0xy-5 ,5 10- trimethyl-5H-[ l benzopyrano [3 ,4-c] piperidine.
(K) 3- 3- 3,4-dimethoxyphenyl propyl] -8-hydr0xy 5,5,10-trimethy1-5H-[1]benzopyrano[3,4-c] piperidine.
(L) 3-[ 1- 2,4,6-tribromophenyl) ethyl] -8-hydroxy- 5 ,5 1 O-trimethyl-S H- l benzopyrano [3 ,4-c] piperidine.
(M) 3- [4-(4-nitrophenyl)butyl] -8-hydroxy-5,5 ,10- trimethyl-SH- l benzopyrano [3,4-c] piperidine.
(N) 3- 2- (4-methylmercaptophenyl ethyl] -8-hydroxy- 5,5 1 O-trimethyl-SH- 1 benzopyrano [3 ,4-c] piperidine.
(O) 3-{3- l- 3,4-methylenedioxyphenyl)- l-butenyl] 8-hydroxy-5 ,5 IO-trimethyl-S H- l benzopyrano [3,4-c] piperidine.
(P) 3-{3- l-(4-acetylaminophenyl) -1-butenyl] }-8- hydroxy-5,5,10-trimethyl-5H-[1]benzopyrano [3 ,4-c] piperidine.
(Q) 3-{4-[1-(3-trifluoromethylphenyl)-1-butenyl]}-8- hydroxy-5 ,5 l O-trimethyl-S H-[ 1 benzopyrano [3,4-c] piperidine.
(R) 3-cyclopropylcarbonyl- 8-hydroxy-5 ,5 IO-trimethyl- 5H-[ IJ-benzopyrano 3 ,4-c] piperidine.
(S) 3-cyclopropylmethyl-8-hydroxy-5 ,5 lO-trimethyl- 5H-[ 1]benzopyrano [3,4-c1piperidine.
(T) 3 3 -pheny1-2-propynyl -8-hydroxy-5 ,5 1 0- trimethyl-5H-[1]benzopyrano[3,4-c]piperidine.
(U) 3-allyl-8-hydroxy-5 ,5 1 O-trimethyl-S H-[ l benzopyrano[3,4-c]piperidine.
(V) 3- (2-propynyl)-8-hydroxy-5,5,IO-trimethyl-SH- l ]benzopyrano [3 ,4-c] piperidine.
(W) 3-(trans-3-chloroallyl)-8-hydroxy-5,5,10-
trimethyl-5H-[1]benzopyrano[3,4-c]piperidine.
(X) 8-acetoxy-3,5,5,l0-tetramethyl-5H[1]benzopyrano [3,4-clpiperidine.
(Y) 8-methoxy-3,5,5,IO-tetramethyl-SH- l] benzopyrano [3 ,4-c] piperidine.
(Z) 8-carbamyloxy-3 ,5 ,5 1 O-tetramethyl-SH- 1 benZopyrano[3,4-c] piperidine.
(AA) 8- (N-methylcarbamyloxy -3 ,5,5, l O-tctramclhyl- 5H-[ 1 benZopyrano[3,4-c] pi peridine.
2 1 (BB) 8- (N,N-dimethylcarbamyloxy -3 ,5 ,5, 10-
tetramethyl-SH- 1] benzopyrano [3,4-c] piperidine. (CC) 8-phosphonyloxy-3 ,5 ,5 1 O-tetramethyl-H- 1 benzopyrano 3,4-c] piperidine.
We claim: 1. A compound having the formula where R is lower-alkyl; R is methyl or 3-methy1-2- octyl; R is hydrogen, lower-alkyl, cycloalkyl-lower-alkyl, containing from three to eight ring carbon atoms in the cycloalkyl moiety, lower-alkenyl, lower-alkynyl, halo-lower-alkenyl and R is hydrogen.
2. A compound according to claim 1 where R and R are hydrogen.
3. A compound according to claim 1 where R, is phenyl-lower-alkyl, and R is hydrogen.
4. A compound according to claim 1 where R is loweralkenyl, and R is hydrogen.
5. A compound according to claim 1 Where R is halolower-alkenyl, and R is hydrogen.
6. A compound according to claim 1 Where R is loweralkynyl, and R is hydrogen.
7. A compound according to claim 1 where R is 3- methyl-Z-octyl; R is lower-alkyl; and R is hydrogen.
8. 5,5 dimethyl hydroXy 8 (3 methyl-L octyl) 1,2,3,4 tetrahydro 5H [1]benzopyran0[3,4-c] pyridine according to claim 2 Where R as lower-alkyl is methyl, and R is 3-methyl-2-octyl.
9. 3 benzyl 5,5 dimethyl 10 hydroxy 8 (3- 22 methyl 2 octyl) 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine according to claim 3 where R as lower-alkyl is methyl; R is 3-methyl-2-octyl; and R as phenyl-lower-alkyl is benzyl.
10. 3 benzyl 1O hydroxy 5,5,8 -trimethy1 1,2,3,4- tetrahydro 5H [1]benzopyrano[3,4-c]pyridine according to claim 3 where R as loWer-alkyl is methyl; R is methyl; and R as phenyl-lower-alkyl is benzyl.
11. 3 allyl 5,5 dimethyl 10 hydroxy 8 (3- methyl 2 octyl) 1,2,3,4 tetrahydro 5H [1]benzo pyrano[3,4-c]pyridine according to claim 4 where R as lower-alkyl is methyl; R is 3-methyl-2-octyl; and R as lower-alkenyl is allyl.
12. 3 (trans 3 chloroallyl) 5,5 dimethyl 10- hydroxy 8 (3 methyl 2 octyl) 1,2,3,4 tetrahydro 5H [1]benzopyrano[3,4-c]pyridine according to claim 5 where R as lower-alkyl is methyl; R is S-methyl- 2-octyl; and R as halo-lower-alkenyl is 3-chloroallyl.
13. 5,5 dimethyl 10 hydroxy 8 (3 methyl 2- octyl) 3 (2 propynyl) 1,2,3,4 tetrahydro 5H- [1]benzopyrano[3,4-c1pyridine according to claim 6 where R as lower-alkyl is methyl; R is 3-methyl-2-octyl; and R as lower-alkynyl is 2-propynyl.
14. 10 hydroxy 8 (3 methyl 2 octyl) 3,5,5- trimethyl 1,2,3,4 tetrahydro 5H [IJbenzopyrano [3,4-c]pyridine according to claim 7 where R and R as lower-alkyl are methyl; and R is 3-methyl-2-octyl.
References Cited UNITED STATES PATENTS 3,522,260 7/1970 Shulgin 260297 3,535,327 10/1970 Pars et al. 260-297 ALAN L. ROTMAN, Primary Examiner US. Cl. X.R.
260294.3 R, 294.7 D, 295 T, 999
UNI T135 STATES P ATENT OFFICE .CERTIFICATE OF CORRECTIQN Patent No. 3,635,993 Dated January 18, 1972 Inventofls) Harry Parsf et al It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 21, line 21, 'after "halo-lower-alkenyl" insert Signed and sealed this 9th day of January 1973.
(SEAL) Attest:
EDWARD M.FLETCHER,JR. ROBERT GOTTSCHALK v Attesting Officer Commissioner of Patents F ORM PO-1050 (10-69) USCOMM-DC GOS'IG-PGQ U.5. GOVERNMENT PRINTING DFFIC E r I969 0-365-334
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64222367A | 1967-05-29 | 1967-05-29 | |
US87027869A | 1969-10-30 | 1969-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3635993A true US3635993A (en) | 1972-01-18 |
Family
ID=27093966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US870278A Expired - Lifetime US3635993A (en) | 1967-05-29 | 1969-10-30 | 1,2,3,4-tetrahydro-5h-(1)benzopyrano-(3,4-a)pyridines |
Country Status (1)
Country | Link |
---|---|
US (1) | US3635993A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3878219A (en) * | 1973-07-13 | 1975-04-15 | Abbott Lab | 5H-{8 1{9 benzopyrano{8 3,4-d{9 pyridines |
US5498419A (en) * | 1994-06-03 | 1996-03-12 | Pars; Harry G. | Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric |
US5760050A (en) * | 1996-03-07 | 1998-06-02 | Warner-Lambert Company | Antipsychotic method utilizing certain tetrahydrochromeno 3,4-c!pyridin-5-ones |
-
1969
- 1969-10-30 US US870278A patent/US3635993A/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3878219A (en) * | 1973-07-13 | 1975-04-15 | Abbott Lab | 5H-{8 1{9 benzopyrano{8 3,4-d{9 pyridines |
US5498419A (en) * | 1994-06-03 | 1996-03-12 | Pars; Harry G. | Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric |
US5760050A (en) * | 1996-03-07 | 1998-06-02 | Warner-Lambert Company | Antipsychotic method utilizing certain tetrahydrochromeno 3,4-c!pyridin-5-ones |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3514464A (en) | 5-oxo-1,2,3,4-tetrahydro-5h-(1)benzopyrano(3,4-c)pyridines | |
US11312723B2 (en) | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | |
US3915996A (en) | Process for making benzopyrans | |
US3655675A (en) | N-(n-heteryl)-acylanilides | |
US3557126A (en) | Derivatives of iboga alkaloids | |
US3429889A (en) | 8 - alkyl - (and 8 - cycloalkyl - lower-alkyl - )10 - hydroxy - 5 - oxo - 1,2,3,4-tetrahydro - 5h(1)benzo - pyrano(3,4 - d) pyridines | |
US3574220A (en) | 1,7-methano-1h-1-benzazepin-5(4h)-ones | |
NZ200631A (en) | 1-substituted spiro-(piperidine-oxo-benzoxamine)s and pharmaceutical compositions | |
PL169740B1 (en) | Method of obtaining novel derivatives of 4h-pyrido-[1,2-a] pyrimidone-4 | |
US3557119A (en) | 2,3,7,8,9,9a-hexahydro-1h-benzo(d,e)(1,7) naphthyridine derivatives | |
US3576798A (en) | 1,2,3,4-tetrahydro-5h-(1)benzopyrano (3,4-d)pyridines | |
EA004500B1 (en) | Antihistaminic spiro compounds | |
KR100315975B1 (en) | 1,2,3,4-Tetrahydro -benzofuro[3,2-c]pyridine derivatives | |
US3314966A (en) | Substituted benzo[a]quinolizines | |
US3635993A (en) | 1,2,3,4-tetrahydro-5h-(1)benzopyrano-(3,4-a)pyridines | |
US3318886A (en) | Substituted 7-hydroxymethyl-7, 8-dihydro-6-amino-6, 14-endoethenocodides and morphide | |
US3888946A (en) | Pyrano benzopyrans | |
US3787424A (en) | Dialkylamino esters of benzopyranopyridines | |
US3878219A (en) | 5H-{8 1{9 benzopyrano{8 3,4-d{9 pyridines | |
US3493579A (en) | 1,4-ethano-5h-(1)benzopyrano (3,4-b)pyridines | |
US3632595A (en) | Compound 2 - benzyl - 10-(1-cyclohexyl-ethyl)-5 5-dimethyl - 8 - hydroxy-1 2 b 4-tetrahydro - 5h - (1)-benzopyrand(3 4-d) pyridine | |
US3717638A (en) | 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR | |
US3331849A (en) | Indolomorphinans and process for their production | |
US3914237A (en) | 5H{8 1{9 benzopyrano-{8 3,4-c{9 piperidines | |
US3929787A (en) | 6,7,8,9-Tetrahydro-pyrido(1,2-a)pyrimidin-4-ones |